ID=H0224
URL=http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/articles/parren99/parren99.html
SIZE=100194
DATE=11/07/2002
TIME=17:02:52
DATASET=Biology
HTML=  
<html>
  <head>
    <title></title>
      <style type="text/css">
	<!--
	  span.red {color: red}
	  span.green {color: green}
          span.small {size:"-1"}
	  input.lavender {background: lavender;
			  color: green}
	  ul.tip {list-style-type: none} 
	  .a11 {color: black; 
                font-size: 11pt; 
                font-weight: normal; 
                text-decoration: none; 
                font-family: Arial, Helvetica, sans-serif}
          a:link {color: blue; 
                  text-decoration : none; 
                  font-weight: normal}
	  a:visited {color : blue;
                     text-decoration : none;
                     font-weight : normal}
          a:hover {color: brown; 
                   text-decoration : none; 
                   font-weight: normal}
#pup {position:absolute; visibility:hidden; z-index:200; width:130; }
//-->
      </style>	
  </head>
  <body bgcolor="white">
    <table bgcolor="white" width="100%" border=0 cellspacing=0 cellpadding=3>
      <tr valign="top">
	<td width="10%" bgcolor="#eaeaea">
               <!--
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>

<HEAD>
  <TITLE>
    HIV sequence database navigation frame
  </TITLE>
</HEAD>


<BODY> 
	BACKGROUND="" 
	BGCOLOR="#eaeaea" 
	TEXT="#000000" 
	LINK="#0000ff" 
	VLINK="#800080" 
	ALINK="#ff0000"
-->

<A HREF="/content/hiv-db/mainpage.html">
	
<IMG SRC="/content/hiv-db/IMAGES/VirusTransparent.gif" BORDER=0></A>

<P>
<CENTER>
</CENTER>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerDatabases.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/mainpage.html" 
	onMouseOver="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/_SequenceDB.gif' "
	onMouseOut="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif' " >
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif" BORDER=0 NAME="Sequence"></A><BR>

<A HREF="http://resdb.lanl.gov/Resist_DB/default.htm" 
	onMouseOver="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/_ResistanceDB.gif' "
	onMouseOut="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif'">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif" BORDER=0 NAME="Resistance"></A><BR>

<A HREF="/content/immunology/index" 
	onMouseOver="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/_ImmunologyDB.gif' "
	onMouseOut="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif" BORDER=0 NAME="Immunology"></A><BR>

<A HREF="/content/vaccine/html/index.html" 
	onMouseOver="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/_VaccinetrialsDB.gif' "
	onMouseOut="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif" BORDER=0 NAME="VaccineTrials"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerPublications.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/HTML/FAQ.html" 
	onMouseOver="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/_FAQ.gif' "
	onMouseOut="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif' ">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif" BORDER=0 NAME="Faq"></A><BR>

<A HREF="/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html" 
	onMouseOver="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/_Alignments.gif' "
	onMouseOut="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif" BORDER=0 NAME="Alignments"></A><BR>

<A HREF="/content/hiv-db/HTML/Tutorials.html" 
	onMouseOver="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tutorials.gif' "
	onMouseOut="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif" BORDER=0 NAME="Tutorials"></A><BR>

<A HREF="/content/hiv-db/REVIEWS/reviews.html" 
	onMouseOver="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/_Reviews.gif' "
	onMouseOut="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif" BORDER=0 NAME="Reviews"></A><BR>

<A HREF="/content/hiv-db/HTML/compendium.html" 
	onMouseOver="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/_Compendia.gif' "
	onMouseOut="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif" BORDER=0 NAME="Compendia"></A><BR>

<A HREF="/content/hiv-db/HTML/links.html" 
	onMouseOver="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/_Links.gif' "
	onMouseOut="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/Links.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Links.gif" BORDER=0 NAME="Links"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerSequenceDB.gif" BORDER=0></A><BR>

<!--
<A HREF="/content/hiv-db/MAP/hivmap.html" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Search&Align.gif'"
	onMouseOut="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif" BORDER=0 NAME="Hivmap"></A><BR>

<!--
<A HREF="/cgi-bin/hivDB3/public/wdb/ssampublic" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/_SearchDB.gif' "
	onMouseOut="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif" BORDER=0 NAME="Searchdb"></A><BR>

<A HREF="/content/hiv-db/HTML/tools.html" 
	onMouseOver="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tools.gif'"
	onMouseOut="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif" BORDER=0 NAME="Tools"></A><BR>

<A HREF="/content/hiv-db/BASIC_BLAST/basic_blast.html" 
	onMouseOver="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/_HIV-BLAST.gif' "
	onMouseOut="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif" BORDER=0 NAME="Hivblast"></A><BR>

<A HREF="http://linker.lanl.gov/RIP/RIPsubmit.html" 
	onMouseOver="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/_Recombination.gif' "
	onMouseOut="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif" BORDER=0 NAME="Rip"></A><BR>

<A HREF="/content/hiv-db/SNAP/WEBSNAP/SNAP.html" 
	onMouseOver="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Syn-Nonsyn.gif' "
	onMouseOut="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif" BORDER=0 NAME="Snap"></A><BR>

<A HREF="/content/hiv-db/HYPERMUT/hypermut.html" 
	onMouseOver="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/_Hypermut.gif' "
	onMouseOut="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif" BORDER=0 NAME="Hypermut"></A><BR>

<A HREF="/content/hiv-db/PCOORD/PCOORD.html" 
	onMouseOver="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/_PCOORD.gif' "
	onMouseOut="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif" BORDER=0 NAME="Pcoord"></A><BR>
    
<A HREF="/content/hiv-db/SUDI/sudi.html" 
	onMouseOver="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/_SUDI.gif' "
	onMouseOut="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif" BORDER=0 NAME="SUDI"></A><BR>

<A HREF="/content/hiv-db/CONTAM/TreeMaker/TreeMaker.html" 
	onMouseOver="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/_TreeMaker.gif' "
	onMouseOut="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif" BORDER=0 NAME="Treemaker"></A><BR>

<A HREF="/content/hiv-db/geography/map_right.html" 
	onMouseOver="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/_Geography.gif' "
	onMouseOut="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif" BORDER=0 NAME="Geography"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<!--
<br>
<small>
<small>
&nbsp;<a href="/content/hiv-db/combined_search/search">Combined Search</a>
</small>
</small>
</CENTER>
-->
<BR>
<BR>

<center>
<small>
<small>
<A HREF="http://www.lanl.gov/misc/disclaimer.html" >Disclaimer/Privacy</A>
</small>
</small>
<FONT FACE="Arial, Helvetica, sans-serif" SIZE="-2">
</FONT>
</center>

<!--
</BODY>
</HTML>
-->


        </td>
	<td>
	  <table border="0" cellspacing="0" cellpadding="3">
	    <tr><td>
            </td></tr>
	    <tr><td><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<!-- This HTML document was generated by PageMaker -->
<!-- On Wed Apr  5 15:13:13 2000 from "ChucksHD:USERS:Chuck:IMMUNO99:4:2-PARREN:Parren.pgm" -->
<HTML>
<HEAD>
<center><img src="../../../IMAGES/newtoplogo2.gif"></center>
<TITLE>Parren99</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">

<!-- Generation of PM publication page 19 -->
<P><B>Neutralizing Epitopes of HIV-1 
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"> Aran F. Labrijn<SUP>1</SUP> and Paul W. H. I. 
Parren<SUP>2</SUP> </B>
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"><I><SUP>1</SUP> Department of Pathophysiology of Plasma Proteins, CLB and Laboratory 
of Experimental and Clinical Immunology, Academic Medical Center, 
University of Amsterdam, Amsterdam, The Netherlands. Email: A_Labrijn@CLB.nl 
<P ALIGN="JUSTIFY"><SUP>2</SUP> The Scripps Research Institute, Department of Immunology, 10550 
North Torrey Pines Road, IMM2, La Jolla, CA 92037. Email: parren@scripps.edu </I>
<P>
<H2>
<B>Introduction</B>
</H2>
<P ALIGN="JUSTIFY">Ideally, a vaccine against human immunodeficiency virus type 1 
(HIV-1) would induce neutralizing antibody levels which would provide 
sterilizing immunity. The levels of antibody required however may not be achievable 
by vaccination (Gauduin <I>et al</I>., 1997; Parren 
<I>et al</I>., 1997; Moore and Burton, 1999; Shibata 
<I>et al</I>., 1999). Nevertheless, neutralizing antibody responses albeit 
of lesser, but still significant potency, will likely be essential in an HIV-1 
vaccine in combination with broadly active cellular responses (Burton and Moore it 
<I>et al</I>., 1998). The necessity or benefit of stimulating B cells that produce 
neutralizing antibodies has been clearly established in murine infection models 
with retroviruses and other RNA viruses (Planz <I>et 
al</I>., 1997; Baldridge <I>et al</I>., 1997; Dittmer 
<I>et al</I>., 1998; Parren <I>et al</I>., 1999; Dittmer 
<I>et al</I>., 1999a; Dittmer <I>et al</I>., 1999b). 
<P ALIGN="JUSTIFY"> Effective vaccines have been developed against a number of viral 
diseases mostly by using empirical methods. Many of these vaccines, including 
those against smallpox, measles and polio, consist of live attenuated viruses. 
Live attenuated viruses have consistently provided protection against infection 
with simian immunodeficiency virus (SIV) and SIV/HIV-1 chimeras in 
non-human primates. Serious safety concerns exist however which preclude the use of 
such vaccines in humans (Ezzel, 1997; Baba <I>et 
al</I>., 1999). The immune correlates of protection against infection of macaque monkeys by live attenuated SIV have 
not been clearly defined and the role of antibodies and cytotoxic 
T-lymphocytes (CTL) have been questioned (Stott and Schild, 1996; Stebbings 
<I>et al</I>., 1998). Protection against SHIV (SIV/HIV chimeras expressing HIV-1 envelope 
glycoprotein) by vaccination with attenuated SIV argues against a role of 
antibodies (Shibata <I>et al</I>., 1997; Wyand <I>et 
al</I>., 1999). A series of elegant experiments inwhich protective immune responses against the Friend retroviral complex 
were dissected however have shown that T cells 
(CD4<SUP>+</SUP> and CD8<SUP>+</SUP>) and B cells 
are required to act in concert to achieve protection against pathogenic challenge 
in mice vaccinated with an attenuated retrovirus (Dittmer 
<I>et al</I>., 1999a). Furthermore, whereas CTL were required to protect against lethal infection, 
neutralizing antibody responses appeared necessary to prevent persistent infection 
(Dittmer <I>et al</I>., 1999b). 
<P ALIGN="JUSTIFY"> Understanding neutralization of HIV-1 primary isolates is important 
for a knowledge-based approach for the development of a vaccine against 
HIV-1. Here we review HIV-1 neutralizing antibodies and their epitopes. 
<H2>
<B>Structure and function of the envelope glycoprotein complex</B>
</H2>
<P ALIGN="JUSTIFY"> The HIV-1 mature envelope glycoprotein complex plays a pivotal role 
in the early events of virus attachment and entry into the target cell. 
Neutralizing antibodies found in the sera of infected individuals are primarily directed 
against this complex. The complex is arranged in a trimeric configuration of 
heterodimers, each consisting of a gp120 surface subunit non-covalently associated with a 
gp41 transmembrane subunit, <I>i.e.,</I> 
(gp120-gp41)<SUB>3</SUB>. By comparing the amino 
acid sequence of gp120 subunits of different HIV-1 isolates, five variable 
regions (V1-V5) and five conserved regions (C1-C5) have been identified (Starcich 
<I>et al</I>., 1986; Modrow <I>et al</I>., 1987). A crystal structure of gp120 lacking the V1, 
V2 and V3 loops and the C and N termini suggests that the gp120 core is 
structurally organized into two major domains, the inner and outer domain, and a 
mini-domain termed the bridging sheet (Fig. 1A) (Kwong 
<I>et al</I>., 1998). The inner domain harbors both the N and C termini of gp120, which are involved in 
the interaction with gp41 (Wyatt <I>et al</I>., 1997), and is the probable site of 
trimer packing (Kwong <I>et al</I>., 1998). The outer domain displays an 
extensively glycosylated surface and as such is effectively concealed from the 
humoral response. The bridging sheet is composed of four antiparallel 
b-sheets extruding from the distal ends of the inner and outer domains. Together with 
additional contributions from the base of the V1/V2 stemloop structure this domain 
forms the conserved co-receptor binding-site. The CD4 binding-site (CD4bs) is 
located within a depression at the interface of the three domains and is relatively 
well conserved between HIV-1 isolates. Although coordinates for the V1, V2, V3 
and V4 loops are missing from the structure, either because they were deleted 
from the gp120 core (V1, V2 and V3) or because of poor resolution (V4), 
their approximate positions can be placed in a model of gp120 based on experimental data in combination with the position of the bases of the loops (Fig. 
1B)(Parren <I>et al</I>., 1999).
<P ALIGN="JUSTIFY"> The aminoterminal ectodomain of the gp41 glycoprotein consists of 
two a-helical regions that are connected by an extended disulfide-stabilized 
loop region. The aminoterminus of gp41 (residues 1&#173;29) contains the 
hydrophobic, glycine rich &quot;fusion peptide&quot; which plays a critical role in the fusion of viral 
and target cell membrane. Three-dimensional structural analysis of peptides 
corresponding to portions of the ectodomain of gp41 reveal a symmetrical trimer 
in complex (Lu <I>et al</I>., 1995; Tan <I>et 
al</I>., 1997; Weissenhorn <I>et al</I>., 1997; Chan 
<I>et al</I>., 1997). In this oligomeric configuration, which probably represents the state 
after triggering of the fusion process (often referred to as the &quot;hairpin&quot; state), 
the aminoterminal a-helices form a central parallel coiled coil, around which 
the carboxyterminal a-helices are packed in an antiparallel arrangement. 
<P ALIGN="JUSTIFY"> The infection process is initiated by attachment of the virus to the 
target cell via the interaction between the gp120 subunit with the cellular receptor 
CD4. The subsequent interactions between gp120 and its co-receptors are complex 
and require conformational changes induced by binding to CD4 (Sattentau 
and Moore, 1991; Sattentau <I>et al</I>., 1993; Thali 
<I>et al</I>., 1993). Presumably, the V1 and V2 loops partially mask both CD4 and chemokine binding sites (Wyatt 
and Sodroski, 1998), and this masking is fully manifested only in mature 
oligomeric gp120 (Fig. 1B). Thus, conformational changes triggered by multivalent 
binding of oligomeric gp120 to a cluster of CD4 molecules displaces the V1, V2 and 
V3 loops and expose the co-receptor binding-site. The flexibility of the 
CD4 molecule allows the gp120, with its co-receptor binding-site exposed, to 
come near the co-receptor for interaction and thus bringing the viral and target 
cell membranes in close proximity. Upon binding to the co-receptor further 
conformational changes result in the destabilization of the gp120-gp41 
interaction. This triggers gp41 to undergo its transition to form a &quot;prehairpin&quot; 
intermediate (Chan and Kim, 1998), which includes the insertion of the fusion peptide of 
gp41 into the target cell membrane and the possible dissociation of the gp120 
subunits. The gp41 than undergoes additional conformational changes resulting in 
the formation of the &quot;hairpin&quot; structure and the fusion of the viral and target 
cell membranes, which finally results in the introduction of the nucleocapsid with 
the viral genome into the host-cell. 
<H2>
<B>Mature oligomeric envelope versus viral debris </B>
</H2>
<P ALIGN="JUSTIFY"> The HIV-1 envelope exists in a number of antigenically distinct forms. It
is synthesized as an envelope precursor molecule gp160, which 
oligomerizes and is cleaved into gp120 and gp41 (Allan 
<I>et al</I>., 1985; Robey <I>et al</I>., 1985). 
The mature functional (gp120-gp41) 3 oligomer on the virion surface tends 
to dissociate (shed) (Poignard <I>et al</I>., 1996a) resulting in the release of 
monomeric gp120 and exposure of gp41 spikes on the virion or infected cell 
surface. Antibodies against HIV-1 envelope in seropositive individuals may be 
elicited by any of these configurations. The following observations have led us 
to conclude that the majority of the response is elicited against the 
unprocessed gp160 or disassembled envelope 
(<I>i.e.,</I> viral debris) rather than the mature oligomer (Parren 
<I>et al</I>., 1997). 1. Antibodies against HIV envelope 
retrieved from HIV-1-infected individuals in general have a much higher affinity 
for unprocessed envelope than for mature oligomeric envelope (Parren 
<I>et al</I>., 1997). 2. Neutralization correlates with antibody binding to mature oligomeric 
envelope (Roben <I>et al</I>., 1994; Sattentau and Moore, 1995; Fouts 
<I>et al</I>., 1997; Parren <I>et al</I>., 1998), and primary isolate (see below) neutralizing antibody titers in 
sera from HIV-1 seropositive individuals are generally poor (Moore 
<I>et al</I>., 1996; Moog <I>et al</I>., 1997; Pilgrim 
<I>et al</I>., 1997). Viral debris rather than virions 
therefore appears to be the primary antigen specificity of antibodies against 
HIV-1 envelope in HIV-1 infected individuals. 
<H2>
<B>T cell line adapted viruses versus primary isolates </B>
</H2>
<P ALIGN="JUSTIFY"> One of the most noticeable influences on HIV-1 neutralization is that 
of the origin of the virus producer cell (reviewed in Moore and Ho, 1995; 
Poignard <I>et al</I>., 1996b). The adaptation of HIV-1 to growth in immortalized CD4+ 
cell lines selects for HIV-1 variants that tend to have a strongly basic V3 
loop (Fouchier <I>et al</I>., 1992), preferentially utilize CXCR4 as a co-receptor 
(reviewed in D'Souza and Harden, 1996; Moore <I>et 
al</I>., 1997; Berger, 1997), and have a high affinity for CD4 (Platt 
<I>et al</I>., 1997; Kozak <I>et al</I>., 1997). These T cell line 
adapted (TCLA) viruses are readily neutralized by sCD4 and a large spectrum of 
different monoclonal antibodies (mAbs) (reviewed in Moore and Ho, 1995). By 
contrast primary isolates, <I>i.e.,</I> viruses obtained by limited passage in primary cultures 
of activated peripheral blood mononuclear cells (PBMC), may use CXCR4 
(termed X4 viruses), CCR5 (R5 viruses) or CXCR4 in combination with CCR5 
(R5X4 viruses) (Berger <I>et al</I>., 1998). They generally have a reduced affinity for 
sCD4 and neutralizing mAbs, and generally display a high degree of resistance 
to neutralization by these ligands (Stamatatos <I>et 
al</I>., 1997; Fouts <I>et al</I>., 1997 and reviewed in Moore and Ho, 1995) (Fig. 2). 

<hr noshade>

<!-- Generation of PM publication page 21 -->

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 LANG=en DIR=LTR WIDTH="792" COLS="11">
<!-- Some browsers do not display table correctly. -->
<!-- The following GIF images are here to work around the problem. -->
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 WIDTH=71><IMG SRC="./HtmlExp.gif" WIDTH=71 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=1><IMG SRC="./HtmlExp.gif" WIDTH=1 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=82><IMG SRC="./HtmlExp.gif" WIDTH=82 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=141><IMG SRC="./HtmlExp.gif" WIDTH=141 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=88><IMG SRC="./HtmlExp.gif" WIDTH=88 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=24><IMG SRC="./HtmlExp.gif" WIDTH=24 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=235><IMG SRC="./HtmlExp.gif" WIDTH=235 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=77><IMG SRC="./HtmlExp.gif" WIDTH=77 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=24><IMG SRC="./HtmlExp.gif" WIDTH=24 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=18><IMG SRC="./HtmlExp.gif" WIDTH=18 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=55><IMG SRC="./HtmlExp.gif" WIDTH=55 HEIGHT=1></TD>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=34>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=4>
<TD COLSPAN=6 HEIGHT=12 WIDTH=466 VALIGN="TOP">

<TD COLSPAN=1 HEIGHT=12>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=14>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=3>
<TD COLSPAN=4 HEIGHT=287 WIDTH=489>
<IMG SRC="./figure1.JPG" WIDTH="489" HEIGHT="287">
<TD COLSPAN=1 HEIGHT=287>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=2>
<TD COLSPAN=3 ROWSPAN=5 HEIGHT=226 WIDTH=312 VALIGN="TOP">
<P 
ALIGN="JUSTIFY">Fig. 1. A model for the structure of monomeric and oligomeric gp120. The 
schematic representation of monomeric gp120 is based on the X-ray crystal structure of the 
HIV-1 gp120 (HxBc2) core in complex with CD4 and mAb 17b (Wyatt 
<I>et al</I>., 1998; Kwong <I>et al</I>., 1998) and reviewed in Parren 
<I>et al</I>., 1999). A) The viewpoint of the model is from 
the target-cell membrane. Three structural elements are shown: the outer domain, the 
inner domain and the bridging sheet. The CD4bs (red oval) is located at the interface of the 
three domains. The conserved co-receptor binding-site (CRbs; yellow circle) is comprised 
of the bridging sheet with additional contributions from the base of the V2 loop. B) 
The location of the variable loops can be placed on the gp120 core, based on experimental 
data from mAb mapping and mutagenesis studies in combination with the position of the 
bases of the loops. The V1/V2 stemloop structure partially masks the CRbs and the CD4bs. 
The inner domain is involved in the interaction with gp41 and is the probable site of 
trimer packing. The outer domain is extensively glycosylated as indicated by the blue dots. 
The 2G12 epitope (purple oval) is located at the base of the V3 and V4 loop and 
probably involves carbohydrate structures. C) Model of mature oligomeric envelope from a 
target-cell viewpoint. The main characteristic of this model is that oligomeric gp120 can 
exist in different conformational states of which the two extremes (a closed state and an 
open state) are shown. In the closed state the masking of the CRbs and the CD4bs by the 
V1/V2 stemloop structure is fully manifested. The V3 loop also partially obscures the 
CRbs and the tip of the V3 loop is relatively inaccessible in this configuration. In the open 
state, the V3 loop is well exposed and the masking of the CD4bs and CRbs by the V1/V2
<TD COLSPAN=1 HEIGHT=31>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=2>
<TD COLSPAN=1>
<TD COLSPAN=2 ROWSPAN=3 HEIGHT=164 WIDTH=312 VALIGN="TOP">
<P 
ALIGN="JUSTIFY">stemloop structure is less evident. Presumably, the oscilation of mature oligomeric 
gp120 of primary isolates has an equilibrium biased in favor of the closed state, whereas 
mature oligomeric gp120 of TCLA viruses is biased toward the open state. 
Neutralization correlates with antibody binding to oligomeric envelope (Roben 
<I>et al</I>., 1994; Sattentau and Moore, 1995; Parren 
<I>et al</I>., 1998) and can be understood in terms of 
epitope accessibility. Epitopes of the CD4bs, V3 loop and CRbs are accessible on TCLA 
envelope and antibodies against these sites neutralize TCLA viruses. These epitopes are 
relatively inaccessible on primary isolate envelope and primary isolates are therefore 
mostly resistant to neutralization by such antibodies. An immunoglobulin molecule (IgG1) 
is depicted next to the oligomeric envelope complex to demonstrate the relative size of 
the neutralizing agent and the accessible surface. With an accessible surface of 
approximately 3000 &Aring;<SUP>2</SUP> on the neutralizing face of gp120, excluding the variable loops (Kwong 
<I>et al</I>., 1998), it can be hypothesized that there is space for three non-competing antibodies 
per gp120 molecule (with a binding area of approximately 800&#173;900 
&Aring;<SUP>2</SUP>). 
<TD COLSPAN=1 HEIGHT=76>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=2>
<TD COLSPAN=1>
<TD COLSPAN=1>
<TD COLSPAN=2 HEIGHT=73 WIDTH=73>

<TD COLSPAN=1 HEIGHT=73>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=15>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=30>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1>
<TD COLSPAN=7 HEIGHT=24 WIDTH=649 VALIGN="TOP">
<P 
ALIGN="CENTER">
<P ALIGN="CENTER"></B>
<TD COLSPAN=1 HEIGHT=24>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=14>
</TABLE>
<hr noshade>

<!-- Generation of PM publication page 22 -->

<TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 LANG=en DIR=LTR WIDTH="792" COLS="10">
<!-- Some browsers do not display table correctly. -->
<!-- The following GIF images are here to work around the problem. -->
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 WIDTH=67><IMG SRC="./HtmlExp.gif" WIDTH=67 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=6><IMG SRC="./HtmlExp.gif" WIDTH=6 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=24><IMG SRC="./HtmlExp.gif" WIDTH=24 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=74><IMG SRC="./HtmlExp.gif" WIDTH=74 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=237><IMG SRC="./HtmlExp.gif" WIDTH=237 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=24><IMG SRC="./HtmlExp.gif" WIDTH=24 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=99><IMG SRC="./HtmlExp.gif" WIDTH=99 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=122><IMG SRC="./HtmlExp.gif" WIDTH=122 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=89><IMG SRC="./HtmlExp.gif" WIDTH=89 HEIGHT=1></TD>
<TD COLSPAN=1 WIDTH=72><IMG SRC="./HtmlExp.gif" WIDTH=72 HEIGHT=1></TD>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=34>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1>
<TD COLSPAN=6 HEIGHT=12 WIDTH=465 
VALIGN="TOP">
<P><B></B>
<TD COLSPAN=1 HEIGHT=12>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=42>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=4>
<TD COLSPAN=4 HEIGHT=355 WIDTH=484>
<IMG SRC="./Figure2.JPG" WIDTH="484" HEIGHT="355">
<TD COLSPAN=1 HEIGHT=355>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=11>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=2 ROWSPAN=2 HEIGHT=73 WIDTH=73>

<TD COLSPAN=1 HEIGHT=11>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1>
<TD COLSPAN=2 ROWSPAN=2 HEIGHT=64 WIDTH=312 VALIGN="TOP">
<P 
ALIGN="JUSTIFY">Fig. 2. An idealized depiction of neutralization resistance of HIV-1 isolates. 
TCLA isolates are highly sensitive to neutralization by antibodies and sCD4 in contrast 
to primary isolates which are relatively neutralization resistant. A bell-shaped curve 
was drawn to depict the fact that the degree of neutralization sensitivity can differ 
significantly between isolates. Some primary isolates (e.g., BZ167) (Moore and Montefiori, 1997) 
are just as sensitive to antibody mediated neutralization as TCLA isolates. Others may be
<TD COLSPAN=1>
<TD COLSPAN=3 ROWSPAN=3 HEIGHT=78 WIDTH=312 VALIGN="TOP">
<P 
ALIGN="JUSTIFY">extraordinarily resistant (e.g., 93US143 and 92US077) (Parren 
<I>et al</I>., 1998). In the evaluation of neutralization data, it is critical to note the neutralization phenotype of 
the isolate used. Neutralization of highly neutralization sensitive isolates by an antibody 
does not predict neutralization of relatively resistant isolates more representative of 
isolates encountered in human infection, and may therefore have little value for the evaluation 
of candidate vaccines. 
<TD COLSPAN=1 HEIGHT=62>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=2>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=13>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=6>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=3>
<TD COLSPAN=6 HEIGHT=24 WIDTH=648 VALIGN="TOP">
<P 
ALIGN="CENTER">
<P ALIGN="CENTER"></B>
<TD COLSPAN=1 HEIGHT=24>
<TR VALIGN="TOP" ALIGN="LEFT">
<TD COLSPAN=1 HEIGHT=38>
</TABLE>
<hr noshade>

<!-- Generation of PM publication page 23 -->

The structural basis for the large difference in neutralization 
sensitivity between TCLA viruses and the majority of primary isolates can be 
understood as follows. It seems likely, based on the gp120 structure that the CD4bs on 
the primary isolate gp120 trimer is more completely masked by the V1 and 
V2 loops than that of TCLA viruses. The idea that gp120 oscillates 
between <I>'</I>'closed' and 'open' states is consistent with the dichotomy of primary 
and TCLA viruses: thus gp120 of primary isolates would have the 
equilibrium biased in favor of a 'closed' conformation, whereas TCLA gp120 would 
be biased towards 'open' (Fig. 1C). In this way, the virus in vivo would 
sacrifice some efficiency in receptor binding for increased resistance to antibody 
attack, whereas cell line-passaged virus would dispense with some now 
unnecessary antibody resistance mechanisms and adapt for more efficient receptor 
interactions instead. This notion appears to be generally applicable to lentiviruses, 
in that SIV, feline immunodeficiency virus (FIV) and equine infectious 
anaemia virus (EIAV) adapt to passage in cell lines in the same way as HIV-1 
does (Baldinotti <I>et al</I>., 1994; Moore <I>et 
al</I>., 1995; Cook <I>et al</I>., 1995; Means <I>et 
al</I>., 1997; Montefiori <I>et al</I>., 1998). 
<P ALIGN="JUSTIFY"> Neutralization sensitivity is an important factor to take into account 
when evaluating HIV-1 neutralization studies. TCLA viruses are highly 
neutralization sensitive (Fig. 2) and it is well recognized that this has misled the HIV-1 
vaccine field for many years (Cohen, 1993). These viruses nevertheless can be 
valuable as they can be used to eliminate a concept from further consideration, as a 
failure to inactivate TCLA HIV-1 <I>in vitro</I> or in vivo would be very discouraging 
(Burton and Moore, 1998). Success with TCLA HIV-1 however should not be 
overemphasized as inactivation of TCLA HIV-1 by an antibody in a neutralization 
assay or an in vivo challenge experiment would be encouraging, but would not 
predict activity against a primary isolate. It is important to note than 
neutralization sensitivities may also differ significantly between primary isolates, as 
indicated by the bell-shaped curve in Fig. 2. Some primary isolates are almost as 
sensitive as TCLA strains (e.g., BZ167)(Moore and Montefiori, 1997), whereas 
others may be exceptionally neutralization resistant (e.g., 92US077)(Parren 
<I>et al</I>., 1998). Arguably, the efficacy of HIV-1 neutralization particularly when 
evaluating candidate vaccines should be assessed with primary isolates of 
intermediate neutralization sensitivity and not with one of the outliers. 
<H2>
<B>The neutralizing antibody response to the HIV-1 envelope complex </B>
</H2>
<P ALIGN="JUSTIFY"> With the recent elucidation of the X-ray crystal structure of gp120
(Kwong <I>et al</I>., 1998), together with earlier mutagenic and antibody 
competition studies (Moore and Sodroski, 1996; Ditzel 
<I>et al</I>., 1997), an antigenic surface map could be constructed, on which the spatial positioning of the neutralizing 
and non-neutralizing epitopes are revealed (Wyatt 
<I>et al</I>., 1998). Neutralizing epitopes on gp120 map to the surface of the envelope complex that is exposed in 
the oligomeric configuration and faces the target cell. For TCLA HIV-1 
isolates strains the neutralizing epitopes include the CD4 and the co-receptor 
binding-sites, the V2 and V3 loops and the unique 2G12 epitope (Table 1). Far 
fewer epitopes are accessible on the mature envelope of primary isolates and 
neutralization of a range of isolates has only been observed with mAb b12 
which recognizes the CD4bs and residues of the V2 loop (Burton 
<I>et al</I>., 1994; Roben <I>et al</I>., 1994; Mo 
<I>et al</I>., 1997) and mAb 2G12 which recognizes an epitope at 
the base of V3 and V4 loop. 
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"><B>Table 1.<I>     </I>Neutralizing epitopes exposed on HIV-1 mature oligomeric
<P ALIGN="JUSTIFY">     envelope </B>
<P ALIGN="JUSTIFY">               Neutralization of
<P ALIGN="JUSTIFY">     Epitope           TCLA     Primary
<P ALIGN="JUSTIFY">     recognized     Antibodies     strains     isolates 
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"><B>gp120</B>
<P ALIGN="JUSTIFY">     V3     loop2, 19b, 447/52D     Yes     No
<P ALIGN="JUSTIFY">     CD4bs     F105, 21h, 15e     Yes     No
<P ALIGN="JUSTIFY">     CD4bs/V2     b12     Yes     Yes 
<P ALIGN="JUSTIFY">     CD4i     17b, 48d     Yes     No 
<P ALIGN="JUSTIFY">     V2     C108G     Yes     
No<SUP>1</SUP>
<P ALIGN="JUSTIFY">          L15, 697D     No     
No<SUP>2</SUP> 
<P ALIGN="JUSTIFY">     base of V3     2G12     Yes     Yes
<P ALIGN="JUSTIFY">      and V4 loop 
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"><B>gp41</B>
<P ALIGN="JUSTIFY">     ELDKWA (residues     2F5     Yes     Yes
<P ALIGN="JUSTIFY">      662&#173;667) 
<P ALIGN="JUSTIFY">
<P ALIGN="JUSTIFY"><SUP>1</SUP> Strain specific neutralization
<P ALIGN="JUSTIFY"><SUP>2</SUP> Some weakly 
<P>

<br>An antigenic surface map has also been proposed for gp41 albeit 
less complete than for gp120 (Binley <I>et al</I>., 1996; Earl 
<I>et al</I>., 1997). These studies identified at least three conformational dependent epitope clusters present 
on native gp41, termed cluster I-III. Antibodies to epitope clusters I and II 
are readily detectable in sera from HIV-1 infected individuals, but most studies 
show that none of the three clusters neutralize TCLA strains or primary isolates 
at biologically relevant concentration (Sattentau 
<I>et al</I>., 1995; Binley <I>et al</I>., 1996). Presumably these epitopes are masked by the gp120 molecules in the 
mature oligomeric envelope complex and thus inaccessible for antibody binding. 
The only epitope that is exposed on mature oligomeric (gp120-associated) gp41 
is defined by the neutralizing mAb 2F5 and is located in the membrane 
proximal part of the ectodomain of gp41 (Table 1 and Muster 
<I>et al</I>., 1993; Muster <I>et al</I>., 1994; Sattentau 
<I>et al</I>., 1995). Studies from one lab have suggested a 
neutralizing epitope within the cytoplasmic domain of gp41 (Chanh 
<I>et al</I>., 1986; Dalgleish <I>et al</I>., 1988; Evans 
<I>et al</I>., 1989), however this has not been confirmed by 
others (D'Souza <I>et al</I>., 1994; D'Souza <I>et 
al</I>., 1995). 
<H2>
<B>Neutralizing Epitopes </B>
</H2>
<H3>
<B> V3</B>
</H3>
<P ALIGN="JUSTIFY">The third variable (V3) loop of gp120 was originally termed the 
principal neutralizing domain (PND), due to its dominant role in the neutralization 
of TCLA strains by sera from HIV-1 infected individuals and gp120 
vaccine recipients. In contrast to the dominant role V3 loop specific mAbs play in 
TCLA strain neutralization, their role in primary isolate neutralization is 
insignificant (VanCott <I>et al</I>., 1995; Spenlehauer 
<I>et al</I>., 1998). This inability of V3 loop specific mAbs to neutralize primary isolates is thought to result from the 
relative inaccessibility of the V3 loop in the native oligomeric envelope complex 
of primary isolates as compared to that of TCLA strains (Bou-Habib 
<I>et al</I>., 1994). Furthermore, because of the hyper-variability of the V3 loop, the mAbs to 
this epitope display a highly strain-specific neutralizing activity. 
<P ALIGN="JUSTIFY"> Binding studies with monomeric gp120-CD4 complexes have 
demonstrated that mAbs to the V3 loop inhibit the interaction of this complex with 
the co-receptor (Wu <I>et al</I>., 1996; Trkola 
<I>et al</I>., 1996a; Hill <I>et al</I>., 1997). 
Although this would suggest neutralization at a post-attachment stage on intact 
virions, anti-V3 loop antibodies neutralize TCLA viruses by inhibiting HIV-1 
attachment to the target cell (Ugolini <I>et 
al</I>., 1997; Valenzuela <I>et al</I>., 1997). 
<H3>
<B> CD4bd</B>
</H3>
<P ALIGN="JUSTIFY">The majority of antibodies to gp120 recognizes discontinuous or 
conformationally sensitive epitopes, of which the CD4 binding domain (CD4bd) is 
the most prevalent (Moore and Ho, 1993). This epitope is defined by mAbs 
that competitively inhibit sCD4 binding to monomeric gp120. As with the 
anti-V3 loop antibodies, early neutralization experiments were biased by the use 
of neutralization sensitive TCLA strains. It has become evident that the majority 
of CD4bd antibodies that could neutralize TCLA strains were unable to 
neutralize primary isolates, with the exception of mAb b12. MAb b12 recognizes 
a conformation dependent epitope that overlaps the CD4bs with some 
involvement of the V2 loop (Roben <I>et al</I>., 1994; Mo 
<I>et al</I>., 1997). Uniquely among the CD4bd specific mAbs, b12 binds equivalently or better to the oligomeric 
form of the envelope glycoprotein (Roben <I>et 
al</I>., 1994; Fouts <I>et al</I>., 1997). 
<H3>
<B> CD4i</B>
</H3>
<P ALIGN="JUSTIFY">A highly conserved but poorly immunogenic epitope is defined by 
mAbs that bind better to gp120 upon complexation with CD4. These antibodies, 
like 17b and 48d (Thali <I>et al</I>., 1993; Wyatt 
<I>et al</I>., 1995), were shown to inhibit the interaction of the gp120-CD4 complex with CCR5 (Wu 
<I>et al</I>., 1996; Trkola <I>et al</I>., 1996a), suggesting that the epitope was located in or near the 
co-receptor binding site. Mutational studies later confirmed that residues within the 
CD4i epitopes were crucial for co-receptor binding (Rizzuto 
<I>et al</I>., 1998). These residues are located primarily in the bridging sheet and may involve 
some residues in the V3 loop. Next to the obvious blocking of co-receptor 
binding, antibodies to CD4i epitopes have been shown to induce gp120 dissociation 
from gp41 (Poignard <I>et al</I>., 1996a). Like the V3 loop, the CD4i epitope is 
a neutralizing epitope only on TCLA strains of HIV-1. Neutralization of 
primary isolates by mAbs against the CD4i epitope has not been observed. 
<H3>
<B> V2</B>
</H3>
<P ALIGN="JUSTIFY">MAbs to the V1/V2 stemloop structure generally recognize 
conformational epitopes which are located in the central region of the V2 loop (Moore 
<I>et al</I>., 1993; McKeating <I>et al</I>., 1993; Gorny 
<I>et al</I>., 1994) and have been shown to neutralize TCLA strains relatively well (Warrier 
<I>et al</I>., 1994). So far mAbs to the V1 part of the stemloop structure have not been identified. Two mAbs 
directed against the V2 loop have been reported to be able to neutralize primary 
isolates (Gorny <I>et al</I>., 1994; Vijh-Warrier 
<I>et al</I>., 1996), although the range of isolates 
that can be neutralized is very limited (Pinter 
<I>et al</I>., 1998). The sequence variability, as with the V3 loop, and additionally a substantial length polymorphism 
make this epitope very strain specific (Wang <I>et 
al</I>., 1995). 

<H3>
<B>2G12</B>
</H3>
<P ALIGN="JUSTIFY">Antibody competition studies identified a unique competition group 
that included a single antibody, 2G12 (Trkola <I>et 
al</I>., 1996b). Based on results from studies involving glycosidase treatment of gp120 and mutagenic alteration 
of N-linked carbohydrate sites, the epitope of this antibody is located at the 
base of the V3 and V4 loop and probably involves carbohydrate structures in the 
C2, C3, C4 and V4 domains (Trkola <I>et al</I>., 1996b). The inclusion of 
carbohydrate structures in the epitope might explain the rarity of this mAb. The 2G12 
epitope is predicted to be oriented towards the target cell upon CD4 binding. This 
would allow the antibody to sterically impair further interactions of the 
membrane complex with the target cell. 
<H3>
<B> 2F5</B>
</H3>
<P ALIGN="JUSTIFY">The only gp41 specific mAb that displays neutralizing activity is 
2F5 (Muster <I>et al</I>., 1993; Muster <I>et 
al</I>., 1994; Conley <I>et al</I>., 1994; Burton, 
1997). This antibody recognizes an epitope that has been mapped to the linear 
sequence ELDKWA, which is located in the membrane proximal part of the 
ectodomain (residues 662&#173;667) (Muster <I>et 
al</I>., 1993) and is the only epitope on gp41 that 
is exposed on the native oligomeric conformation of the HIV-1 envelope 
glycoprotein complex (Muster <I>et al</I>., 1993; Muster 
<I>et al</I>., 1994; Sattentau <I>et al</I>., 
1995). MAb 2F5 does not interfere with virus attachment to the target cell, 
but neutralizes at a later stage (Ugolini <I>et 
al</I>., 1997). 
<H2>
<B> Neutralization mechanisms</B>
</H2>
<P ALIGN="JUSTIFY">The principal mechanism of antibody-mediated neutralization 
for HIV-1 is the inhibition of attachment of the virus to the target cell 
(Ugolini <I>et al</I>., 1997). This was found to be independent of the epitope 
cluster recognized by the neutralizing mAb (Parren 
<I>et al</I>., 1998). 
<P ALIGN="JUSTIFY"> Several mechanisms to inhibit attachment can be envisioned 
and have been proposed (Dimmock, 1995). Aggregation has been shown to 
be effective in neutralizing poliovirus or human rhinovirus (reviewed 
in Dimmock, 1995), however the observations that monovalent ligands 
neutralize as well as bivalent ones argues against a role of this mechanism 
in HIV-1 neutralization (Parren <I>et al</I>., 1998). Furthermore, the 
bell-shaped curve associated with this mechanism has not been described for 
HIV-1 (McLain and Dimmock, 1994) and aggregates could not be recovered 
in neutralizing antibody-treated HIV-1 preparations (McDougal 
<I>et al</I>., 1996). The absence of neutralization of amphotropic murine leukemia virus
<TD COLSPAN=1>
<TD COLSPAN=1 ROWSPAN=2 HEIGHT=468 WIDTH=306 VALIGN="TOP">
<P 
ALIGN="JUSTIFY">(AMLV) envelope-mediated infection of AMLV/HIV-1 
envelope pseudotyped virions by a neutralizing antibody against HIV-1 
finally suggests that virion aggregation is not a neutralization mechanism 
for HIV-1 (Sch&oslash;nning <I>et al</I>., 1999). 
<P ALIGN="JUSTIFY"> With one observed exception all effectively 
HIV-1-neutralizing mAbs block virus attachment to the target cell either by inhibiting 
the interaction with CD4 or the co-receptor (Wu 
<I>et al</I>., 1996; Trkola <I>et al</I>., 1996a; Ugolini 
<I>et al</I>., 1997). The absence of an epitope bias suggests 
that any antibody capable of binding to the limited surface of gp120 that 
is exposed in the mature oligomer (Fig. 1C) can effectively block 
interaction with the receptor binding sites (Parren 
<I>et al</I>., 1998). For attachment of virus to the target cell to occur, presumably multiple contacts in a 
localized area must be established. Coating of the viral surface with 
antibodies obstructs the close approach of the virus to the target cell, 
thereby preventing attachment and initiation of a fusion event (Parren 
<I>et al</I>., 1998). Such a mechanism is in good agreement with an elegant study on 
stoichiometry of mAb mediated neutralization. In this study, neutralization 
could be explained with an incremental model in which neutralization 
occurs incrementally as each envelope molecule binds mAb (Sch&oslash;nning 
<I>et al</I>., 1999). Although the studies above were performed with TCLA strains 
of HIV-1 rather than primary isolates for practical reasons, there is 
no indication that the general conclusions from these studies do not apply 
to primary isolates. To explain the relative neutralization resistance 
of primary isolates compared to TCLA strains, a theoretical model has 
been proposed (Klasse and Moore, 1996). It predicts that neutralization is 
the result of the reduction of the number of functional envelope 
molecules below a critical threshold. Neutralization resistance of primary isolates 
is explained by affinity of antibodies to primary isolate envelope and 
a higher number of envelope spikes per primary isolate virion (Klasse 
and Moore, 1996). Envelope density as a modifier of neutralization 
however is not consistent with an incremental model (Sch&oslash;nning 
<I>et al</I>., 1999). It has been demonstrated furthermore that neither increased spike density 
nor spike stability could account for the neutralization resistance of 
primary isolates (Karlsson <I>et al</I>., 1996). The mechanism of primary isolate 
neutralization and neutralization resistance therefore require further study. 
Convincing data however support an incremental mechanism in which 
coating of virions with antibody prevent attachment to the target cell and 
neutralization potency is determined by antibody affinity for the mature 
envelope oligomer. 

<P 
ALIGN="JUSTIFY"> The one exception on the principal neutralization mechanism is 
constituted by the gp41 specific mAb 2F5, which does not inhibit virus attachment 
to the target cell, but neutralizes at a later stage (Ugolini 
<I>et al</I>., 1997). The exact mechanism by which this epitope mediates neutralization of the virus is 
unclear, but the epitope is located near a conserved tryptophan-rich region that has 
been implemented in env-mediated fusion (Salzwedel 
<I>et al</I>., 1999). Mutations in the epitope had only a limited effect on cell-cell fusion, which makes it unlikely 
that this epitope is directly involved in the fusion process (Salzwedel 
<I>et al</I>., 1999). A hypothetical mechanism for neutralization could be that 2F5 interferes at 
some stage with the completion of the transition of the non-fusogenic state to the 
post-fusion state (Binley and Moore, 1997; Chan and Kim, 1998). 
<H2>
<B>Relevance of <I>in vitro</I> neutralization data </B>
</H2>
<P ALIGN="JUSTIFY"> The neutralizing activity of a mAb is measured 
<I>in vitro</I> in the absence of complement and antibody-dependent cell-mediated cytotoxicity. 
This would suggest an underestimation of the neutralizing efficacy of a mAb 
in vivo. However with the emergence of more data on the inactivation of 
the virus in animal models, it has become clear that there is generally a 
good correlation between the <I>in vitro</I> and in vivo results (Parren 
<I>et al</I>., 1995; Gauduin <I>et al</I>., 1995; Gauduin 
<I>et al</I>., 1997; Mascola <I>et al</I>., 1999; Shibata 
<I>et al</I>., 1999). The studies show that when a mAb is capable of neutralizing 
the challenge virus <I>in vitro</I> , sterilizing immunity can be obtained at 
concentrations in the order of 1&#173;2 logs greater than those needed for 90 
neutralization <I>in vitro</I> (Parren <I>et 
al</I>., 1997). To achieve protection, serum 
neutralizing antibody levels that are sufficient to inactivate virtually all the virus in 
an <I>in vitro</I> assay need to be achieved. Failure to obtain adequate antibody 
titers leads to establishment of infection and cell-to-cell virus 
transmission, which requires considerable higher antibody concentrations than 
those needed to block cell-free virus (Pantaleo 
<I>et al</I>., 1995). Once HIV-1 infection is established, even high levels of neutralizing antibody have no or only 
very limited effects on an ongoing infection (Poignard 
<I>et al</I>., 1999). This is not to say that pre-existing neutralizing antibody concentrations below 
the levels that would provide sterilizing immunity have no effect upon 
viral challenge. Studies on murine retroviruses and other RNA viruses 
have indicated that a reduction of the viral inoculum by neutralizing 
antibodies may provide a benefit by giving time to the cellular immune response 
to develop (Planz <I>et al</I>., 1997; Baldridge 
<I>et al</I>., 1997; Dittmer <I>et al</I>., 1998; Parren 
<I>et al</I>., 1999; Dittmer <I>et al</I>., 1999a; Dittmer 
<I>et al</I>., 1999b). A reduction
of pathogenicity has furthermore been observed in passive 
neutralizing antibody transfer studies in macaques and chimpanzees. (Conley 
<I>et al</I>., 1996; Mascola <I>et al</I>., 1999). 
<H2>
<B>Additional effects of polyclonality </B>
</H2>
<P ALIGN="JUSTIFY"> The HIV-1 neutralizing activity found in the polyclonal antisera 
from infected individuals is the combined result of the neutralizing abilities of 
the distinct Abs. A handful of studies have looked at the combined effects of 
mAbs with different specificities on the neutralization of TCLA strains (Kennedy 
<I>et al</I>., 1991; McKeating <I>et al</I>., 1992; Tilley 
<I>et al</I>., 1992; Potts <I>et al</I>., 1993; Laal 
<I>et al</I>., 1994; Vijh-Warrier <I>et al</I>., 1996) and primary isolates (Mascola 
<I>et al</I>., 1997) <I>in vitro</I>. These studies demonstrate a neutralizing effect that is greater than the 
sum of separate neutralizing abilities of the tested Abs, or synergy. However, 
the observed synergy is generally weak and could only be shown with 
mathematical models. The biological relevance of this mechanism is unknown, as it is hard 
to interpret the situation in vivo. One passive antibody transfer study 
which assessed the combination of two neutralizing mAbs (2F5 and 2G12) 
together with HIVIG in a model with SHIV 89.6PD in pigtail macaques, demonstrated 
a general correlation between the synergistic effects on neutralization observed 
<I>in vitro</I> and the protection in vivo (Mascola 
<I>et al</I>., 1997; Mascola <I>et al</I>., 1999). 
In severe combined immunodeficient mice reconstituted with human 
peripheral blood lymphocytes (hu-PBL-SCID mice), a cocktail of 2F5, 2G12 and 
b12 reduced the viral RNA titer during established infection, whereas b12 alone 
had no detectable effect (Poignard <I>et al</I>., 1999). This synergy however can 
be explained by the necessity of individual viruses to acquire multiple amino 
acid mutations for neutralization escape rather than by binding cooperativity effects. 
<H2>
<B>Novel neutralizing epitopes </B>
</H2>
<P ALIGN="JUSTIFY"> The primary isolate neutralizing antibodies identified so far are 
directed to epitopes which are present on the resting oligomeric envelope. It may 
be envisioned that epitopes which are exposed on the activated (after CD4 
binding) or fusogenic state of the membrane complex (after complexation with the 
co-receptor) are interesting targets for antibody neutralization. The main 
epitope that becomes exposed after interaction with CD4 is the CD4i epitope 
overlapping the co-receptor binding-site. MAbs to this epitope isolated to date do not 
display primary isolate neutralizing activity at relevant concentrations. It can 
however not be excluded that more potent antibodies do exist. 

<P 
ALIGN="JUSTIFY"> The fusiogenic state of gp41 has previously been identified as a target 
for neutralization by studies using peptides that mimic the carboxyterminal 
helices of gp41 (Jiang <I>et al</I>., 1993; Wild 
<I>et al</I>., 1994). The peptides were able to 
inhibit the fusion process quite efficiently. It is possible that the dimensions of a 
full immunoglobulin molecule are a limiting factor in the accessibility of 
these neutralization sensitive sites. However, a recent study in which fusing cells 
were fixed using formalin, suggests the presence of yet unidentified 
neutralizing epitopes on the fusogenic state of the membrane complex (LaCasse 
<I>et al</I>., 1999). This observation suggests that the rarity of these types of antibodies may be 
due to a temporal rather than a physical constraint. However, to date no definite 
proof has been provided that the mouse sera recognize epitopes on the viral 
proteins and not cellular antigens (Montefiori and Moore, 1999). 
<H2>
<B>Non-envelope mediated neutralization </B>
</H2>
<P ALIGN="JUSTIFY"> Several examples of neutralization 
<I>in vitro</I> have been described, which are mediated by antibodies that are not directed to the envelope complex. 
The majority of non-envelope neutralizing antibodies is directed at cellular 
membrane proteins. During the budding process HIV-1 acquires a variety of 
cellular proteins on its membrane (Arthur <I>et 
al</I>., 1992; Tremblay <I>et al</I>., 1998), 
although the diversity of the proteins present on the membrane is probably an 
overestimation due to contamination of the virion preparations with microparticles 
(Raposo <I>et al</I>., 1996; Gluschankof <I>et 
al</I>., 1997; Bess <I>et al</I>., 1997; Dettenhofer and 
Yu, 1999). Antibodies to several of these host cell derived proteins have been 
shown to neutralize <I>in vitro</I>. Most notable are the antibodies to the receptor-ligand 
pair ICAM-1 (intercellular adhesion molecule-1; CD54) and LFA-1 
(leukocyte function-associated molecule-1; CD11a/CD18) (Gomez and Hildreth, 
1995; Rizzuto and Sodroski, 1997). Also antibodies to HLA-DR, 
2-microglobuline and HLA class I have been shown to neutralize 
<I>in vitro</I> (Arthur <I>et al</I>., 1992). As inhibition of attachment is a major mechanism of neutralization of 
HIV-1 (Ugolini <I>et al</I>., 1997) it may be that antibodies to these proteins present on 
the virion membrane interfere with binding of the envelope complex to the 
receptors on the target cell. Alternatively, the incorporation of MHC class II 
enhances virus entry into the target cell (Cantin 
<I>et al</I>., 1997). By blocking this interaction the infection process is less effective, which may contribute to the 
neutralizing activity observed. 
<P ALIGN="JUSTIFY"> Protection against infection with SIV grown in human cells has 
been consistently observed in monkeys after active or passive immunization 
against host cell components (Arthur <I>et al</I>., 1995; Stott and Schild, 1996). The impor
tance of antibody mediated neutralization via these self-antigens in humans 
is unclear. It is suggestive that the extent of HLA mismatch between mother 
and child and relative rarity of certain HLA haplotypes in commercial sex 
workers have been shown to correlate with the risk for seroconversion. 
However, antibodies against HLA class I allotypes do not appear to contribute to 
resistance against HIV-1 infection in exposed uninfected sex workers (reviewed in 
Plummer <I>et al</I>., 1999). 
<P ALIGN="JUSTIFY"> Host-derived cyclophilin A is specifically incorporated into HIV-1 
virions through interactions with the gag protein and is required for infection. It 
has been suggested that cyclophilin A may play a role in virus-cell fusion and 
that antibodies against cyclophilin A may inhibit HIV-1 infection (Sherry 
<I>et al</I>., 1998). Additional studies however are necessary to explain how cyclophilin 
A, which is localized inside the virion, may become accessible to 
neutralizing antibodies. It has been suggested that anti-cyclophilin A antibodies could 
play a role in a vaccine against HIV-1 (Sherry <I>et 
al</I>., 1998). As cyclophilin A is a self-protein, however, it is very unlikely that effective and safe responses could 
be elicited. 
<P ALIGN="JUSTIFY"> During natural infection the viral regulatory protein Tat is released 
from productively infected cells (Ensoli <I>et 
al</I>., 1993; Westendorp <I>et al</I>., 1995; 
Chang <I>et al</I>., 1997) where in turn it may transactivate virus replication in the 
neighboring cells (Frankel and Pabo, 1988; Ensoli 
<I>et al</I>., 1993). Extracellular Tat also induces co-receptor expression and thereby facilitating HIV-1 transmission 
(Li <I>et al</I>., 1997; Huang <I>et al</I>., 1998). Antibodies against Tat were shown to 
inhibit HIV-1 IIIb replication <I>in vitro</I> and correlate with non-progression in vivo (Re 
<I>et al</I>., 1995; Zagury <I>et al</I>., 1998). These results indicate a possible role for 
anti-Tat antibodies in controlling HIV-1 infection. In a study in cynomolgus 
monkeys vaccinated with a Tat vaccine however control of pathogenic SHIV 
89.6P infection did not correlate with Tat-neutralizing antibody levels (Cafaro 
<I>et al</I>., 1999). 
<H2>
<B>Conclusions </B>
</H2>
<P ALIGN="JUSTIFY"> HIV-1 sensitivity to neutralization is determined to some extent by the 
cell in which the virus was grown, less so by the target cell and co-receptor 
used. Increased accessibility of epitopes on the mature oligomeric envelope of 
TCLA viruses probably determines their relative sensitivity to neutralization as 
compared to primary isolates (summarized in Fig. 1). The principal mechanism 
of neutralization of HIV-1 most likely is an incremental mechanism in 
which coating of virions with antibody prevents attachment to the target cell and
neutralization potency is determined by antibody affinity for the mature 
envelope oligomer. 
<P ALIGN="JUSTIFY"> A number of common neutralizing epitopes have been identified 
on TCLA HIV-1 gp120. Most of these epitopes, however, including 
relatively immunogenic epitopes overlapping the CD4bs and V3 loop have shown to 
be mostly irrelevant for the neutralization of HIV-1 primary isolates. Only 
two epitopes on gp120 appear to be accessible on primary isolate envelope 
and conserved on a broad spectrum of isolates: an epitope which involves 
residues of the CD4bs and the V2 loop recognized by mAb b12 and an epitope at the 
base of V3 and V4 loop recognized by mAb 2G12. Both these epitopes are 
poorly immunogenic and antibodies with b12 and 2G12 specificity are rarely elicited 
in the humoral response after HIV-1 infection. A single neutralizing epitope 
has been defined on HIV-1 gp41. This epitope recognized by mAb 2F5 is 
relatively conserved, poorly immunogenic and is accessible on TCLA as well as 
primary isolate oligomeric envelope. 
<P ALIGN="JUSTIFY"> Neutralization of HIV-1 <I>in 
vitro</I> is a good measure of the antiviral 
activity of a given antibody preparation. There is a good correlation between 
neutralization <I>in vitro</I> and protection: antibody concentrations that neutralize all 
the challenge virus in an <I>in vitro</I> assay can provide sterilizing immunity in vivo. 
Pre-existing neutralizing antibody concentrations at insufficient levels to 
provide sterilizing immunity may decrease pathogenicity by reducing the viral 
inoculum and clearing infected cells, thereby allowing more time for the cellular 
immune response to mature. Once HIV-1 infection is established, however, even 
high levels of neutralizing antibody have no or only very limited effects on an 
ongoing infection. 
<P ALIGN="JUSTIFY"> There are many indications that a vaccine that would effectively 
elicit high affinity antibodies against conserved epitopes accessible on mature 
oligomeric envelope of HIV-1 primary isolates would have a major impact on 
HIV-1 transmission. Poorly immunogenic epitopes defined by mAb b12, 2G12 
and 2F5, represent the relevant vaccine targets on the HIV-1 envelope 
structure identified to date. 
<H2>
<B>References </B>
</H2>
<P ALIGN="JUSTIFY">Allan, J. S., Coligan, J. E., Barin, F., McLane, M. F., Sodroski, J. G., Rosen, 
C. A., Haseltine, W. A., Lee, T. H., and Essex, M. (1985). Major 
glycoprotein antigens that induce antibodies in AIDS patients are encoded by 
HTLV-III. <I>Science</I> <B>228:</B>1091&#173;1094. 

<P 
ALIGN="JUSTIFY">Arthur, L. O., Bess, J. W. J., Sowder, R. C., Benveniste, R. E., Mann, D. 
L., Chermann, J. C., and Henderson, L. E. (1992). Cellular proteins bound 
to immunodeficiency viruses: implications for pathogenesis and 
vaccines. <I>Science</I> <B>258:</B>1935&#173;1938. 
<P ALIGN="JUSTIFY">Arthur, L. O., Bess, J. W. J., Urban, R. G., Strominger, J. L., Morton, W. 
R., Mann, D. L., Henderson, L. E., and Benveniste, R. E. (1995). 
Macaques immunized with HLA-DR are protected from challenge with 
simian immunodeficiency virus. <I>J. Virol.</I> 
<B>69:</B>3117&#173;3124. 
<P ALIGN="JUSTIFY">Baba, T. W., Liska, V., Khimani, A. H., Ray, N. B., Dailey, P. J., Penninck, 
D., Bronson, R., Greene, M. F., McClure, H. M., Martin, L. N., and 
Ruprecht, R. M. (1999). Live attenuated, multiply deleted simian 
immunodeficiency virus causes AIDS in infant and adult macaques. 
<I>Nat. Med</I> <B>5:</B>194&#173;203. 
<P ALIGN="JUSTIFY">Baldinotti, F., Matteucci, D., Mazzetti, P., Giannelli, C., Bandecchi, P., 
Tozzini, F., and Bendinelli, M. (1994). Serum neutralization of feline 
immunodeficiency virus is markedly dependent on passage history of the virus and 
host system. <I>J. Virol.</I> <B>68:</B>4572&#173;4579. 
<P ALIGN="JUSTIFY">Baldridge, J. R., McGraw, T. S., Paoletti, A., and Buchmeier, M. J. 
(1997). Antibody prevents the establishment of persistent arenavirus infection 
in synergy with endogenous T cells. <I>J. 
Virol.</I> <B>71:</B>755&#173;758. 
<P ALIGN="JUSTIFY">Berger, E. A. (1997). HIV entry and tropism: the chemokine receptor 
connection. <I>AIDS Suppl</I> A:S3-16. 
<P ALIGN="JUSTIFY">Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R., 
Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., and Weiss, R. 
A. (1998). A new classification for HIV-1. <I>Nature 
</I><B>391:</B>240. 
<P ALIGN="JUSTIFY">Bess, J. W. J., Gorelick, R. J., Bosche, W. J., Henderson, L. E., and Arthur, 
L. O. (1997). Microvesicles are a source of contaminating cellular 
proteins found in purified HIV-1 preparations. 
<I>Virology</I> <B>230:</B>134&#173;144. 
<P ALIGN="JUSTIFY">Binley, J. and Moore, J. P. (1997). HIV-cell fusion. The viral mousetrap. 
<I>Nature </I><B>387</B>:346&#173;348. 
<P ALIGN="JUSTIFY">Binley, J. M., Ditzel, H. J., Barbas, C. F., Sullivan, N., Sodroski, J., Parren, P. 
W., and Burton, D. R. (1996). Human antibody responses to HIV type 
1 glycoprotein 41 cloned in phage display libraries suggest three 
major epitopes are recognized and give evidence for conserved antibody 
motifs in antigen binding. <I>AIDS Res. Hum. 
Retroviruses</I> 12:<B>911</B>&#173;924. 
<P>Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P., 
and Norcross, M. A. (1994). Cryptic nature of envelope V3 region 
epitopes protects primary monocytotropic human immunodeficiency virus type 
1 from antibody neutralization. <I>J. Virol.</I> 
<B>68</B>:6006&#173;6013. 
<P ALIGN="JUSTIFY">Burton, D. R. (1997). A vaccine for HIV type 1: the antibody perspective. 
<I>Proc. Natl. Acad. Sci U. S. A.</I> <B>94:</B>10018&#173;10023. 
<P ALIGN="JUSTIFY">Burton, D. R. and Moore, J. P. (1998). Why do we not have an HIV vaccine 
and how can we make one? <I>Nat. Med</I> <B>4:</B>495&#173;498. 
<P ALIGN="JUSTIFY">Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. 
W. H. I., Sawyer, L. S., Hendry, R. M., Dunlop, N., and Nara, P. L. 
(1994). Efficient neutralization of primary isolates of HIV-1 by a 
recombinant human monoclonal antibody. 
<I>Science</I> <B>266:</B>1024&#173;1027. 
<P ALIGN="JUSTIFY">Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M. T., Goletti, D., 
Baroncelli, S., Pace, M., Sernicola, L., Koanga-Mogtomo, M. L., Betti, M., 
Borsetti, A., Belli, R., Akerblom, L., Corrias, F., Butto, S., Heeney, J., Verani, 
P., Titti, F., and Ensoli, B. (1999). Control of SHIV-89. 6P-infection 
of cynomolgus monkeys by HIV-1 Tat protein vaccine. 
<I>Nat. Med</I> <B>5:</B>643&#173;650. 
<P ALIGN="JUSTIFY">Cantin, R., Fortin, J. F., Lamontagne, G., and Tremblay, M. (1997). 
The acquisition of host-derived major histocompatibility complex class 
II glycoproteins by human immunodeficiency virus type 1 accelerates 
the process of virus entry and infection in human T-lymphoid cells. 
<I>Blood</I> <B>90</B>:1091&#173;1100. 
<P ALIGN="JUSTIFY">Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997). Core structure of 
gp41 from the HIV envelope glycoprotein. 
<I>Cell</I> <B>89</B>:263&#173;273. 
<P ALIGN="JUSTIFY">Chan, D. C. and Kim, P. S. (1998). HIV entry and its inhibition. 
<I>Cell</I> <B>93</B>:681&#173;684. 
<P ALIGN="JUSTIFY">Chang, H. C., Samaniego, F., Nair, B. C., Buonaguro, L., and Ensoli, B. 
(1997). HIV-1 Tat protein exits from cells via a leaderless secretory pathway 
and binds to extracellular matrix-associated heparan sulfate 
proteoglycans through its basic region. 
<I>AIDS</I> <B>11</B>:1421&#173;1431. 
<P ALIGN="JUSTIFY">Chanh, T. C., Dreesman, G. R., Kanda, P., Linette, G. P., Sparrow, J. T., Ho, 
D. D., and Kennedy, R. C. (1986). Induction of anti-HIV neutralizing 
antibodies by synthetic peptides. <I>EMBO J</I>. 
<B>5</B>:3065&#173;3071. 
<P ALIGN="JUSTIFY">Cohen, J. (1993). Jitters jeopardize AIDS vaccine trials. 
<I>Science</I> <B>262</B>:980&#173;981.
<P 
ALIGN="JUSTIFY">Conley, A. J., Kessler, J. A., Boots, L. J., Tung, J. S., Arnold, B. A., Keller, 
P. M., Shaw, A. R., and Emini, E. A. (1994). Neutralization of 
divergent human immunodeficiency virus type 1 variants and primary isolates 
by IAM-41-2F5, an anti-gp41 human monoclonal antibody. 
<I>Proc. Natl. Acad. Sci U. S. A.</I> <B>91</B>:3348&#173;3352. 
<P ALIGN="JUSTIFY">Conley, A. J., Kessler, J. A., II, Boots, L. J., McKenna, P. M., Schleif, W. 
A., Emini, E. A., Mark, G. E., III, Katinger, H., Cobb, E. K., Lunceford, S. 
M., Rouse, S. R., and Murthy, K. K. (1996). The consequence of 
passive administration of an anti-human immunodeficiency virus type 1 
neutralizing monoclonal antibody before challenge of chimpanzees with a 
primary virus isolate. <I>J. Virol.</I> <B>70</B>:6751&#173;6758. 
<P ALIGN="JUSTIFY">Cook, R. F., Berger, S. L., Rushlow, K. E., McManus, J. M., Cook, S. J., 
Harrold, S., Raabe, M. L., Montelaro, R. C., and Issel, C. J. (1995). 
Enhanced sensitivity to neutralizing antibodies in a variant of equine 
infectious anemia virus is linked to amino acid substitutions in the surface 
unit envelope glycoprotein. <I>J. Virol.</I> 
<B>69</B>:1493&#173;1499. 
<P ALIGN="JUSTIFY">D'Souza, M. P., Geyer, S. J., Hanson, C. V., Hendry, R. M., and Milman, 
G. (1994). Evaluation of monoclonal antibodies to HIV-1 envelope by 
neutralization and binding assays: an international collaboration. 
<I>AIDS</I> <B>8</B>:169&#173;181. 
<P ALIGN="JUSTIFY">D'Souza, M. P. and Harden, V. A. (1996). Chemokines and HIV-1 
second receptors. Confluence of two fields generates optimism in AIDS 
research. <I>Nat. Med</I> <B>2</B>:1293&#173;1300. 
<P ALIGN="JUSTIFY">D'Souza, M. P., Milman, G., Bradac, J. A., McPhee, D., Hanson, C. V., 
and Hendry, R. M. (1995). Neutralization of primary HIV-1 isolates by 
anti-envelope monoclonal antibodies. <I>AIDS</I> 
<B>9</B>:867&#173;874. 
<P ALIGN="JUSTIFY">Dalgleish, A. G., Chanh, T. C., Kennedy, R. C., Kanda, P., Clapham, P. R., 
and Weiss, R. A. (1988). Neutralization of diverse HIV-1 strains by 
monoclonal antibodies raised against a gp41 synthetic peptide. 
<I>Virology</I> <B>165</B>:209&#173;215. 
<P ALIGN="JUSTIFY">Dettenhofer, M. and Yu, X. F. (1999). Highly purified human 
immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. 
<I>J. Virol.</I> <B>73</B>:1460&#173;1467. 
<P ALIGN="JUSTIFY">Dimmock, N. J. (1995). Update on the neutralisation of animal viruses. 
Reviews in Medical <I>Virology</I> <B>5</B>:165&#173;179. 

<P 
ALIGN="JUSTIFY">Dittmer, U., Brooks, D. M., and Hasenkrug, K. J. (1998). Characterization of 
a live-attenuated retroviral vaccine demonstrates protection via 
immune mechanisms. <I>J. Virol.</I> <B>72</B>:6554&#173;6558. 
<P ALIGN="JUSTIFY">Dittmer, U., Brooks, D. M., and Hasenkrug, K. J. (1999a). Requirement 
for multiple lymphocyte subsets in protection by a live attenuated 
vaccine against retroviral infection. <I>Nat. 
Med</I> <B>5</B>:189&#173;193. 
<P ALIGN="JUSTIFY">Dittmer, U., Race, B., and Hasenkrug, K. J. (1999b). Kinetics of the 
development of protective immunity in mice vaccinated with a live attenuated 
retrovirus. <I>J. Virol.</I> <B>73</B>:8435&#173;8440. 
<P ALIGN="JUSTIFY">Ditzel, H. J., Parren, P. W. H. I., Binley, J. M., Sodroski, J., Moore, J. P., 
Barbas, C. F., and Burton, D. R. (1997). Mapping the protein surface of 
human immunodeficiency virus type 1 gp120 using human monoclonal 
antibodies from phage display libraries. <I>J. Mol. 
Biol</I> <B>267</B>:684&#173;695. 
<P ALIGN="JUSTIFY">Earl, P. L., Broder, C. C., Doms, R. W., and Moss, B. (1997). Epitope map 
of human immunodeficiency virus type 1 gp41 derived from 47 
monoclonal antibodies produced by immunization with oligomeric envelope protein. 
<I>J. Virol.</I> <B>71</B>:2674&#173;2684. 
<P ALIGN="JUSTIFY">Ensoli, B., Buonaguro, L., Barillari, G., Fiorelli, V., Gendelman, R., Morgan, 
R. A., Wingfield, P., and Gallo, R. C. (1993). Release, uptake, and effects 
of extracellular human immunodeficiency virus type 1 Tat protein on 
cell growth and viral transactivation. <I>J. 
Virol.</I> <B>67</B>:277&#173;287. 
<P ALIGN="JUSTIFY">Evans, D. J., McKeating, J., Meredith, J. M., Burke, K. L., Katrak, K., John, 
A., Ferguson, M., Minor, P. D., Weiss, R. A., and Almond, J. W. (1989). 
An engineered poliovirus chimaera elicits broadly reactive HIV-1 
neutralizing antibodies. <I>Nature </I><B>339</B>:385&#173;8, 340. 
<P ALIGN="JUSTIFY">Ezzel, C. (1997). The monkeys got AIDS: what now for live AIDS 
vaccines? <I>Journal of NIH Research</I> <B>9</B>:21&#173;22. 
<P ALIGN="JUSTIFY">Fouchier, R. A., Groenink, M., Kootstra, N. A., Tersmette, M., Huisman, H. 
G., Miedema, F., and Schuitemaker, H. (1992). Phenotype-associated 
sequence variation in the third variable domain of the human 
immunodeficiency virus type 1 gp120 molecule. <I>J. 
Virol.</I> <B>66</B>:3183&#173;3187. 
<P ALIGN="JUSTIFY">Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E., and Moore, J. P. 
(1997). Neutralization of the human immunodeficiency virus type 1 
primary isolate JR-FL by human monoclonal antibodies correlates with antibody
binding to the oligomeric form of the envelope glycoprotein complex. 
<I>J. Virol.</I> <B>71</B>:2779&#173;2785. 
<P ALIGN="JUSTIFY">Frankel, A. D. and Pabo, C. O. (1988). Cellular uptake of the tat protein 
from human immunodeficiency virus. <I>Cell</I> 
<B>55</B>:1189&#173;1193. 
<P ALIGN="JUSTIFY">Gauduin, M. C., Parren, P. W. H. I., Weir, R., Barbas, C. F., Burton, D. R., 
and Koup, R. A. (1997). Passive immunization with a human 
monoclonal antibody protects hu-PBL-SCID mice against challenge by primary 
isolates of HIV-1. <I>Nat. Med</I> <B>3</B>:1389&#173;1393. 
<P ALIGN="JUSTIFY">Gauduin, M. C., Safrit, J. T., Weir, R., Fung, M. S., and Koup, R. A. (1995). 
Pre- and postexposure protection against human immunodeficiency virus 
type 1 infection mediated by a monoclonal antibody. 
<I>J. Infect. Dis</I>. <B>171</B>:1203&#173;1209. 
<P ALIGN="JUSTIFY">Gluschankof, P., Mondor, I., Gelderblom, H. R., and Sattentau, Q. J. (1997). 
Cell membrane vesicles are a major contaminant of gradient-enriched 
human immunodeficiency virus type-1 preparations. 
<I>Virology</I> <B>230</B>:125&#173;133. 
<P ALIGN="JUSTIFY">Gomez, M. B. and Hildreth, J. E. (1995). Antibody to adhesion molecule 
LFA-1 enhances plasma neutralization of human immunodeficiency virus 
type 1. <I>J. Virol<B>.</B></I><B> 69</B>:4628&#173;4632. 
<P ALIGN="JUSTIFY">Gorny, M. K., Moore, J. P., Conley, A. J., Karwowska, S., Sodroski, J., 
Williams, C., Burda, S., Boots, L. J., and Zolla-Pazner, S. (1994). Human 
anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates 
of human immunodeficiency virus type 1. <I>J. 
Virol.</I> <B>68</B>:8312&#173;8320. 
<P ALIGN="JUSTIFY">Hill, C. M., Deng, H., Unutmaz, D., Kewalramani, V. N., Bastiani, L., Gorny, 
M. K., Zolla-Pazner, S., and Littman, D. R. (1997). Envelope 
glycoproteins from human immunodeficiency virus types 1 and 2 and simian 
immunodeficiency virus can use human CCR5 as a coreceptor for viral entry 
and make direct CD4-dependent interactions with this chemokine receptor. 
<I>J. Virol.</I> <B>71</B>:6296&#173;6304. 
<P ALIGN="JUSTIFY">Huang, L., Bosch, I., Hofmann, W., Sodroski, J., and Pardee, A. B. (1998). 
Tat protein induces human immunodeficiency virus type 1 (HIV-1) 
coreceptors and promotes infection with both macrophage-tropic and T- 
lymphotropic HIV-1 strains. <I>J. Virol.</I> 
<B>72</B>:8952&#173;8960. 
<P ALIGN="JUSTIFY">Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993). HIV-1 inhibition by 
a peptide. <I>Nature </I><B>365</B>:113.
<P>Karlsson, G. B., Gao, F., Robinson, J., Hahn, B., and Sodroski, J. 
(1996). Increased envelope spike density and stability are not required for 
the neutralization resistance of primary human immunodeficiency viruses. 
<I>J. Virol.</I> <B>70</B>:6136&#173;6142. 
<P ALIGN="JUSTIFY">Kennedy, M. S., Orloff, S., Ibegbu, C. C., Odell, C. D., Maddon, P. J., 
and McDougal, J. S. (1991). Analysis of synergism/antagonism between 
HIV-1 antibody-positive human sera and soluble CD4 in blocking 
HIV-1 binding and infectivity. <I>AIDS Res. Hum. 
Retroviruses</I> <B>7</B>:975&#173;981. 
<P ALIGN="JUSTIFY">Klasse, P. J. and Moore, J. P. (1996). Quantitative model of antibody- and 
soluble CD4-mediated neutralization of primary isolates and T-cell 
line-adapted strains of human immunodeficiency virus type 1. 
<I>J. Virol.</I> <B>70</B>:3668&#173;3677. 
<P ALIGN="JUSTIFY">Kozak, S. L., Platt, E. J., Madani, N., Ferro, F. E. J., Peden, K., and Kabat, 
D. (1997). CD4, CXCR-4, and CCR-5 dependencies for infections by 
primary patient and laboratory-adapted isolates of human immunodeficiency 
virus type 1. <I>J. Virol.</I> <B>71</B>:873&#173;882. 
<P ALIGN="JUSTIFY">Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., 
and Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope 
glycoprotein in complex with the CD4 receptor and a neutralizing 
human antibody. <I>Nature </I><B>393</B>:648&#173;659. 
<P ALIGN="JUSTIFY">Laal, S., Burda, S., Gorny, M. K., Karwowska, S., Buchbinder, A., and 
Zolla-Pazner, S. (1994). Synergistic neutralization of human 
immunodeficiency virus type 1 by combinations of human monoclonal antibodies. 
<I>J. Virol.</I> <B>68</B>:4001&#173;4008. 
<P ALIGN="JUSTIFY">LaCasse, R. A., Follis, K. E., Trahey, M., Scarborough, J. D., Littman, D. R., 
and Nunberg, J. H. (1999). Fusion-competent vaccines: broad neutralization 
of primary isolates of HIV. <I>Science</I> 
<B>283</B>:357&#173;362. 
<P ALIGN="JUSTIFY">Li, C. J., Ueda, Y., Shi, B., Borodyansky, L., Huang, L., Li, Y. Z., and 
Pardee, A. B. (1997). Tat protein induces self-perpetuating permissivity for 
productive HIV-1 infection. <I>Proc. Natl. Acad. Sci U. S. 
A.</I> <B>94</B>:8116&#173;8120.
<P ALIGN="JUSTIFY">Lu, M., Blacklow, S. C., and Kim, P. S. (1995). A trimeric structural domain 
of the HIV-1 transmembrane glycoprotein. <I>Nat. Struct. 
Biol</I> <B>2</B>:1075&#173;1082. 
<P ALIGN="JUSTIFY">Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, 
D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, 
M. L., Katinger, H., and Birx, D. L. (1999). Protection of Macaques against
pathogenic simian/human immunodeficiency virus 89. 6PD by 
passive transfer of neutralizing antibodies. <I>J. 
Virol.</I> <B>73</B>:4009&#173;4018. 
<P ALIGN="JUSTIFY">Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. 
S., Muenz, L. R., Bunow, B., Birx, D. L., and Robb, M. L. (1997). Potent 
and synergistic neutralization of human immunodeficiency virus (HIV) type 
1 primary isolates by hyperimmune anti-HIV immunoglobulin 
combined with monoclonal antibodies 2F5 and 2G12. 
<I>J. Virol.</I> <B>71</B>:7198&#173;7206. 
<P ALIGN="JUSTIFY">McDougal, J. S., Kennedy, M. S., Orloff, S. L., Nicholson, J. K., and Spira, 
T. J. (1996). Mechanisms of human immunodeficiency virus Type 1 
(HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 
antibody. <I>J. Virol.</I> <B>70</B>:5236&#173;5245. 
<P ALIGN="JUSTIFY">McKeating, J. A., Cordell, J., Dean, C. J., and Balfe, P. (1992). 
Synergistic interaction between ligands binding to the CD4 binding site and V3 
domain of human immunodeficiency virus type I gp120. 
<I>Virology</I> <B>191</B>:732&#173;742. 
<P ALIGN="JUSTIFY">McKeating, J. A., Shotton, C., Cordell, J., Graham, S., Balfe, P., Sullivan, 
N., Charles, M., Page, M., Bolmstedt, A., and Olofsson, S. (1993). 
Characterization of neutralizing monoclonal antibodies to linear and 
conformation-dependent epitopes within the first and second variable domains of 
human immunodeficiency virus type 1 gp120. <I>J. 
Virol.</I> <B>67</B>:4932&#173;4944. 
<P ALIGN="JUSTIFY">McLain, L. and Dimmock, N. J. (1994). Single- and multi-hit kinetics 
of immunoglobulin G neutralization of human immunodeficiency virus 
type 1 by monoclonal antibodies. <I>J. Gen. 
Virol</I>. <B>75</B>:1457&#173;1460. 
<P ALIGN="JUSTIFY">Means, R. E., Greenough, T., and Desrosiers, R. C. (1997). 
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. 
<I>J. Virol.</I> <B>71</B>:7895&#173;7902. 
<P ALIGN="JUSTIFY">Mo, H., Stamatatos, L., Ip, J. E., Barbas, C. F., Parren, P. W., Burton, D. 
R., Moore, J. P., and Ho, D. D. (1997). Human immunodeficiency virus 
type 1 mutants that escape neutralization by human monoclonal 
antibody IgG1b12. <I>J. Virol.</I> <B>71</B>:6869&#173;6874. 
<P ALIGN="JUSTIFY">Modrow, S., Hahn, B. H., Shaw, G. M., Gallo, R. C., Wong-Staal, F., and 
Wolf, H. (1987). Computer-assisted analysis of envelope protein sequences 
of seven human immunodeficiency virus isolates: prediction of 
antigenic epitopes in conserved and variable regions. 
<I>J. Virol.</I> <B>61</B>:570&#173;578. 
<P ALIGN="JUSTIFY">Montefiori, D. and Moore, J. P. (1999). HIV vaccines. Magic of the occult?
<I>Science</I> <B>283</B>:336&#173;337. 
<P ALIGN="JUSTIFY">Montefiori, D. C., Reimann, K. A., Wyand, M. S., Manson, K., Lewis, M. 
G., Collman, R. G., Sodroski, J. G., Bolognesi, D. P., and Letvin, N. L. 
(1998). Neutralizing antibodies in sera from macaques infected with 
chimeric simian-human immunodeficiency virus containing the envelope 
glycoproteins of either a laboratory-adapted variant or a primary isolate of 
human immunodeficiency virus type 1. <I>J. 
Virol.</I> <B>72</B>:3427&#173;3431. 
<P ALIGN="JUSTIFY">Moog, C., Fleury, H. J., Pellegrin, I., Kirn, A., and Aubertin, A. M. 
(1997). Autologous and heterologous neutralizing antibody responses 
following initial seroconversion in human immunodeficiency virus type 
1-infected individuals. <I>J. Virol.</I> <B>71</B>:3734&#173;3741. 
<P ALIGN="JUSTIFY">Moore, J. P. and Burton, D. R. (1999). HIV-1 neutralizing antibodies: how 
full is the bottle? <I>Nat. Med</I> <B>5</B>:142&#173;144. 
<P ALIGN="JUSTIFY">Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B., and Ho, D. D. (1996). 
Inter- and intraclade neutralization of human immunodeficiency virus type 
1: genetic clades do not correspond to neutralization serotypes but 
partially correspond to gp120 antigenic serotypes. 
<I>J. Virol.</I> <B>70</B>:427&#173;444. 
<P ALIGN="JUSTIFY">Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., 
Robinson, J., Barbas, C. F., Burton, D. R., and Ho, D. D. (1995). Primary isolates 
of human immunodeficiency virus type 1 are relatively resistant to 
neutralization by monoclonal antibodies to gp120, and their neutralization is 
not predicted by studies with monomeric gp120. <I>J. 
Virol.</I> <B>69</B>:101&#173;109. 
<P ALIGN="JUSTIFY">Moore, J. P. and Ho, D. D. (1993). Antibodies to discontinuous or 
conformationally sensitive epitopes on the gp120 glycoprotein of human 
immunodeficiency virus type 1 are highly prevalent in sera of infected humans. 
<I>J. Virol.</I> <B>67</B>:863&#173;875. 
<P ALIGN="JUSTIFY">Moore, J. P. and Ho, D. D. (1995). HIV-1 neutralization: the consequences 
of viral adaptation to growth on transformed T cells. 
<I>AIDS</I> Suppl A:S117-S136 .
<P ALIGN="JUSTIFY">Moore, J. P. and Montefiori, D. C. (1997). Neutralization assays using the 
BZ167 strain of human immunodeficiency virus type 1. 
<I>J. Infect. Dis.</I> <B>176</B>:1410&#173;1412. 
<P ALIGN="JUSTIFY">Moore, J. P., Sattentau, Q. J., Yoshiyama, H., Thali, M., Charles, M., 
Sullivan, N., Poon, S. W., Fung, M. S., Traincard, F., and Pinkus, M. (1993). Probing

<P 
ALIGN="JUSTIFY">the structure of the V2 domain of human immunodeficiency virus type 
1 surface glycoprotein gp120 with a panel of eight monoclonal 
antibodies: human immune response to the V1 and V2 domains. 
<I>J. Virol.</I> <B>67</B>:6136&#173;6151. 
<P ALIGN="JUSTIFY">Moore, J. P. and Sodroski, J. (1996). Antibody cross-competition analysis of 
the human immunodeficiency virus type 1 gp120 exterior envelope 
glycoprotein. <I>J. Virol.</I> <B>70</B>:1863&#173;1872. 
<P ALIGN="JUSTIFY">Moore, J. P., Trkola, A., and Dragic, T. (1997). Co-receptors for HIV-1 
entry. <I>Curr. Opin. Immunol</I> <B>9</B>:551&#173;562. 
<P ALIGN="JUSTIFY">Muster, T., Guinea, R., Trkola, A., Purtscher, M., Klima, A., Steindl, F., 
Palese, P., and Katinger, H. (1994). Cross-neutralizing activity against 
divergent human immunodeficiency virus type 1 isolates induced by the 
gp41 sequence ELDKWAS. <I>J. Virol.</I> <B>68</B>:4031&#173;4034. 
<P ALIGN="JUSTIFY">Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., 
Ruker, F., and Katinger, H. (1993). A conserved neutralizing epitope on gp41 
of human immunodeficiency virus type 1. <I>J. 
Virol.</I> <B>67</B>:6642&#173;6647. 
<P ALIGN="JUSTIFY">Pantaleo, G., Demarest, J. F., Vaccarezza, M., Graziosi, C., Bansal, G. 
P., Koenig, S., and Fauci, A. S. (1995). Effect of anti-V3 antibodies on 
cell-free and cell-to-cell human immunodeficiency virus transmission. 
<I>Eur. J. Immunol</I> <B>25</B>:226&#173;231. 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Burton, D. R., and Sattentau, Q. J. (1997). HIV-1 
antibody&#173;debris or virion? <I>Nat. Med</I> 
<B>3</B>:366&#173;367. 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Ditzel, H. J., Gulizia, R. J., Binley, J. M., Barbas, C. 
F., Burton, D. R., and Mosier, D. E. (1995). Protection against HIV-1 
infection in hu-PBL-SCID mice by passive immunization with a neutralizing 
human monoclonal antibody against the gp120 CD4-binding site. 
<I>AIDS</I> , F1-F6 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Gauduin, M. C., Koup, R. A., Poignard, P., Sattentau, Q. 
J., Fisicaro, P., and Burton, D. R. (1997). Relevance of the antibody 
response against human immunodeficiency virus type 1 envelope to vaccine 
design. <I>Immunol Lett</I>. <B>58</B>:125&#173;132. 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Mondor, I., Naniche, D., Ditzel, H. J., Klasse, P. J., 
Burton, D. R., and Sattentau, Q. J. (1998). Neutralization of human 
immunodeficiency virus type 1 by antibody to gp120 is determined primarily 
by occupancy of sites on the virion irrespective of epitope specificity. 
<I>J. Virol.</I>
<B>72</B>:3512&#173;3519. 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Moore, J. P., Burton, D. R., and Sattentau, Q. J. (1999). 
The neutralizing antibody response to HIV-1: viral evasion and escape 
from humoral immunity. <I>AIDS</I> (suppl A), S137-S162 
<P ALIGN="JUSTIFY">Parren, P. W. H. I., Wang, M., Trkola, A., Binley, J. M., Purtscher, M., 
Katinger, H., Moore, J. P., and Burton, D. R. (1998). Antibody 
neutralization-resistant primary isolates of human immunodeficiency virus type 1. 
<I>J. Virol.</I> <B>72</B>:10270&#173;10274. 
<P ALIGN="JUSTIFY">Pilgrim, A. K., Pantaleo, G., Cohen, O. J., Fink, L. M., Zhou, J. Y., Zhou, J. 
T., Bolognesi, D. P., Fauci, A. S., and Montefiori, D. C. (1997). 
Neutralizing antibody responses to human immunodeficiency virus type 1 in 
primary infection and long-term-nonprogressive infection. 
<I>J. Infect. Dis</I>. <B>176</B>:924&#173;932. 
<P ALIGN="JUSTIFY">Pinter, A., Honnen, W. J., Kayman, S. C., Trochev, O., and Wu, Z. (1998). 
Potent neutralization of primary HIV-1 isolates by antibodies directed 
against epitopes present in the V1/V2 domain of HIV-1 gp120. 
<I>Vaccine </I><B>16</B>:1803&#173;1811. 
<P ALIGN="JUSTIFY">Planz, O., Ehl, S., Furrer, E., Horvath, E., Brundler, M. A., Hengartner, H., 
and Zinkernagel, R. M. (1997). A critical role for 
neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and 
acute infections of mice with lymphocytic choriomeningitis virus: 
implications for adoptive immunotherapy of virus carriers. 
<I>Proc. Natl. Acad. Sci U. S. A.</I> <B>94</B>:6874&#173;6879. 
<P ALIGN="JUSTIFY">Platt, E. J., Madani, N., Kozak, S. L., and Kabat, D. (1997). Infectious 
properties of human immunodeficiency virus type 1 mutants with distinct 
affinities for the CD4 receptor. <I>J. Virol.</I> 
<B>71</B>:883&#173;890. 
<P ALIGN="JUSTIFY">Plummer, F. A., Ball, T. B., Kimani, J., and Fowke, K. R. (1999). Resistance 
to HIV-1 infection among highly exposed sex workers in Nairobi: 
what mediates protection and why does it develop? 
<I>Immunol Lett</I>. <B>66</B>:27&#173;34. 
<P ALIGN="JUSTIFY">Poignard, P., Fouts, T., Naniche, D., Moore, J. P., and Sattentau, Q. J. 
(1996a). Neutralizing antibodies to human immunodeficiency virus type-1 
gp120 induce envelope glycoprotein subunit dissociation. 
<I>J. Exp. Med</I> <B>183</B>:473&#173;484. 
<P ALIGN="JUSTIFY">Poignard, P., Klasse, P. J., and Sattentau, Q. J. (1996b). Antibody neutralizationof HIV-1. <I>Immunol Today</I> 
<B>17</B>:239&#173;246. 
<P ALIGN="JUSTIFY">Poignard, P., Sabbe, R., Picchio, G. R., Wang, M., Gulizia, R. J., Katinger, 
H., Parren, P. W. H. I., Mosier, D. E., and Burton, D. R. (1999). 
Neutralizing antibodies have limited effects on the control of established HIV-1 
infection in vivo. <I>Immunity </I><B>10</B>:431&#173;438. 
<P ALIGN="JUSTIFY">Potts, B. J., Field, K. G., Wu, Y., Posner, M., Cavacini, L., and White-Scharf, 
M. (1993). Synergistic inhibition of HIV-1 by CD4 binding domain 
reagents and V3- directed monoclonal antibodies. 
<I>Virology</I> <B>197</B>:415&#173;419. 
<P ALIGN="JUSTIFY">Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. 
V., Melief, C. J., and Geuze, H. J. (1996). B lymphocytes secrete 
antigen-presenting vesicles. <I>J. Exp. Med</I> 
<B>183</B>:1161&#173;1172. 
<P ALIGN="JUSTIFY">Re, M. C., Furlini, G., Vignoli, M., Ramazzotti, E., Roderigo, G., De Rosa, 
V., Zauli, G., Lolli, S., Capitani, S., and La Placa, M. (1995). Effect of 
antibody to HIV-1 Tat protein on viral replication 
<I>in vitro</I> and progression of HIV-1 disease in vivo. 
<I>J. Acquir. Immune. Defic. Syndr. Hum. 
Retrovirol</I>. <B>10</B>:408&#173;416. 
<P ALIGN="JUSTIFY">Rizzuto, C. D. and Sodroski, J. G. (1997). Contribution of virion ICAM-1 
to human immunodeficiency virus infectivity and sensitivity to 
neutralization. <I>J. Virol.</I> <B>71</B>:4847&#173;4851. 
<P ALIGN="JUSTIFY">Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. 
D., Hendrickson, W. A., and Sodroski, J. (1998). A conserved HIV 
gp120 glycoprotein structure involved in chemokine receptor binding. 
<I>Science</I> <B>280</B>:1949&#173;1953. 
<P ALIGN="JUSTIFY">Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., and Burton, D. 
R. (1994). Recognition properties of a panel of human recombinant 
Fab fragments to the CD4 binding site of gp120 that show differing abilities 
to neutralize human immunodeficiency virus type 1. 
<I>J. Virol.</I> <B>68</B>:4821&#173;4828. 
<P ALIGN="JUSTIFY">Robey, W. G., Safai, B., Oroszlan, S., Arthur, L. O., Gonda, M. A., Gallo, R. 
C., and Fischinger, P. J. (1985). Characterization of envelope and core 
structural gene products of HTLV- III with sera from AIDS patients. 
<I>Science</I> <B>228</B>:593&#173;595. 
<P ALIGN="JUSTIFY">Salzwedel, K., West, J. T., and Hunter, E. (1999). A conserved 
tryptophan-rich motif in the membrane-proximal region of the human 
immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and
virus infectivity. <I>J. 
Virol.</I> <B>73</B>:2469&#173;2480. 
<P ALIGN="JUSTIFY">Sattentau, Q. J. and Moore, J. P. (1991). Conformational changes induced in 
the human immunodeficiency virus envelope glycoprotein by soluble 
CD4 binding. <I>J. Exp</I>. Med <B>174</B>:407&#173;415. 
<P ALIGN="JUSTIFY">Sattentau, Q. J. and Moore, J. P. (1995). Human immunodeficiency virus 
type 1 neutralization is determined by epitope exposure on the gp120 
oligomer. <I>J. Exp. Med</I> <B>182</B>:185&#173;196. 
<P ALIGN="JUSTIFY">Sattentau, Q. J., Moore, J. P., Vignaux, F., Traincard, F., and Poignard, P. 
(1993). Conformational changes induced in the envelope glycoproteins of 
the human and simian immunodeficiency viruses by soluble receptor 
binding. <I>J. Virol.</I> <B>67</B>:7383&#173;7393. 
<P ALIGN="JUSTIFY">Sattentau, Q. J., Zolla-Pazner, S., and Poignard, P. (1995). Epitope exposure 
on functional, oligomeric HIV-1 gp41 molecules. 
<I>Virology</I> <B>206</B>:713&#173;717. 
<P ALIGN="JUSTIFY">Sch&oslash;nning, K., Lund, O., S&oslash;gaard, L. O., and Stig, H. J. (1999). 
Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human 
immunodeficiency virus type 1. <I>J. Virol.</I> 
<B>73</B>:8364&#173;8370. 
<P ALIGN="JUSTIFY">Sherry, B., Zybarth, G., Alfano, M., Dubrovsky, L., Mitchell, R., Rich, 
D., Ulrich, P., Bucala, R., Cerami, A., and Bukrinsky, M. (1998). Role 
of cyclophilin A in the uptake of HIV-1 by macrophages and T 
lymphocytes. <I>Proc. Natl. Acad. Sci U. S. A.</I> 
<B>95</B>:1758&#173;1763. 
<P ALIGN="JUSTIFY">Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, 
W., Willey, R., Cho, M. W., and Martin, M. A. (1999). Neutralizing 
antibody directed against the HIV-1 envelope glycoprotein can completely 
block HIV-1/SIV chimeric virus infections of macaque monkeys. 
<I>Nat. Med</I> <B>5</B>:204&#173;210. 
<P ALIGN="JUSTIFY">Shibata, R., Siemon, C., Czajak, S. C., Desrosiers, R. C., and Martin, M. 
A. (1997). Live, attenuated simian immunodeficiency virus vaccines 
elicit potent resistance against a challenge with a human 
immunodeficiency virus type 1 chimeric virus. <I>J. 
Virol.</I> <B>71</B>:8141&#173;8148. 
<P ALIGN="JUSTIFY">Spenlehauer, C., Saragosti, S., Fleury, H. J., Kirn, A., Aubertin, A. M., 
and Moog, C. (1998). Study of the V3 loop as a target epitope for 
antibodies involved in the neutralization of primary isolates versus 
T-cell-line-adapted strains of human immunodeficiency virus type 1. 
<I>J. Virol.</I> <B>72</B>:9855&#173;9864. 
<P 
ALIGN="JUSTIFY">Stamatatos, L., Zolla-Pazner, S., Gorny, M. K., and Cheng-Mayer, C. 
(1997). Binding of antibodies to virion-associated gp120 molecules of 
primary- like human immunodeficiency virus type 1 (HIV-1) isolates: effect 
on HIV-1 infection of macrophages and peripheral blood mononuclear 
cells. <I>Virology</I> <B>229</B>:360&#173;369. 
<P ALIGN="JUSTIFY">Starcich, B. R., Hahn, B. H., Shaw, G. M., McNeely, P. D., Modrow, S., 
Wolf, H., Parks, E. S., Parks, W. P., Josephs, S. F., and Gallo, R. C. 
(1986). Identification and characterization of conserved and variable regions in 
the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. 
<I>Cell</I> <B>45</B>:637&#173;648. 
<P ALIGN="JUSTIFY">Stebbings, R., Stott, J., Almond, N., Hull, R., Lines, J., Silvera, P., Sangster, 
R., Corcoran, T., Rose, J., Cobbold, S., Gotch, F., McMichael, A., and 
Walker, B. (1998). Mechanisms of protection induced by attenuated simian 
immunodeficiency virus. II. Lymphocyte depletion does not abrogate 
protection. <I>AIDS Res. Hum. Retroviruses</I> 
<B>14</B>:1187&#173;1198.
<P ALIGN="JUSTIFY">Stott, E. J. and Schild, G. C. (1996). Strategies for AIDS vaccines. 
<I>J. Antimicrob. Chemother</I>. <B>37 </B>Suppl B:185&#173;198. 
<P ALIGN="JUSTIFY">Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997). Atomic structure of 
a thermostable subdomain of HIV-1 gp41. <I>Proc. Natl. Acad. Sci U. S. 
A.</I> <B>94</B>:12303&#173;12308. 
<P ALIGN="JUSTIFY">Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J., 
and Sodroski, J. (1993). Characterization of conserved human 
immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon 
gp120-CD4 binding. <I>J. Virol.</I> <B>67</B>:3978&#173;3988. 
<P ALIGN="JUSTIFY">Tilley, S. A., Honnen, W. J., Racho, M. E., Chou, T. C., and Pinter, A. 
(1992). Synergistic neutralization of HIV-1 by human monoclonal 
antibodies against the V3 loop and the CD4-binding site of gp120. 
<I>AIDS Res. Hum. Retroviruses</I> <B>8</B>:461&#173;467. 
<P ALIGN="JUSTIFY">Tremblay, M. J., Fortin, J. F., and Cantin, R. (1998). The acquisition of 
host-encoded proteins by nascent HIV-1. <I>Immunol Today 
</I><B>19</B>:346&#173;351. 
<P ALIGN="JUSTIFY">Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. 
P., Cheng-Mayer, C., Robinson, J., Maddon, P. J., and Moore, J. P. 
(1996a). CD4-dependent, antibody-sensitive interactions between HIV-1 and its 
co- receptor CCR-5. <I>Nature</I> <B>384</B>:184&#173;187. 
<P 
ALIGN="JUSTIFY">Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, 
N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H. (1996b). 
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope 
on the gp120 glycoprotein of human immunodeficiency virus type 1. 
<I>J. Virol.</I> <B>70</B>:1100&#173;1108. 
<P ALIGN="JUSTIFY">Ugolini, S., Mondor, I., Parren, P. W. H. I., Burton, D. R., Tilley, S. A., 
Klasse, P. J., and Sattentau, Q. J. (1997). Inhibition of virus attachment to 
CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 
neutralization. <I>J. Exp. Med</I> <B>186</B>:1287&#173;1298. 
<P ALIGN="JUSTIFY">Valenzuela, A., Blanco, J., Krust, B., Franco, R., and Hovanessian, A. G. 
(1997). Neutralizing antibodies against the V3 loop of human 
immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding 
of virus to cells. <I>J. Virol.</I> <B>71</B>:8289&#173;8298. 
<P ALIGN="JUSTIFY">VanCott, T. C., Polonis, V. R., Loomis, L. D., Michael, N. L., Nara, P. L., 
and Birx, D. L. (1995). Differential role of V3-specific antibodies in 
neutralization assays involving primary and laboratory-adapted isolates of HIV 
type 1. <I>AIDS Res. Hum. Retroviruses</I> 
<B>11</B>:1379&#173;1391. 
<P ALIGN="JUSTIFY">Vijh-Warrier, S., Pinter, A., Honnen, W. J., and Tilley, S. A. (1996). 
Synergistic neutralization of human immunodeficiency virus type 1 by a 
chimpanzee monoclonal antibody against the V2 domain of gp120 in combination 
with monoclonal antibodies against the V3 loop and the CD4- binding site. 
<I>J. Virol.</I> <B>70</B>:4466&#173;4473. 
<P ALIGN="JUSTIFY">Wang, N., Zhu, T., and Ho, D. D. (1995). Sequence diversity of V1 and 
V2 domains of gp120 from human immunodeficiency virus type 1: lack 
of correlation with viral phenotype. <I>J. 
Virol.</I> <B>69</B>:2708&#173;2715. 
<P ALIGN="JUSTIFY">Warrier, S. V., Pinter, A., Honnen, W. J., Girard, M., Muchmore, E., and 
Tilley, S. A. (1994). A novel, glycan-dependent epitope in the V2 domain 
of human immunodeficiency virus type 1 gp120 is recognized by a 
highly potent, neutralizing chimpanzee monoclonal antibody. 
<I>J. Virol.</I> 68:4636&#173;4642. 
<P ALIGN="JUSTIFY">Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. 
C. (1997). Atomic structure of the ectodomain from HIV-1 gp41. 
<I>Nature</I> <B>387</B>:426&#173;430. 

<P 
ALIGN="JUSTIFY">Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., 
Walczak, H., Debatin, K. M., and Krammer, P. H. (1995). Sensitization of T cells 
to CD95-mediated apoptosis by HIV-1 Tat and gp120. 
<I>Nature</I> <B>375</B>:497&#173;500. 
<P ALIGN="JUSTIFY">Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and 
Matthews, T. J. (1994). Peptides corresponding to a predictive alpha-helical 
domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of 
virus infection. <I>Proc. Natl. Acad. Sci U. S. 
A.</I> <B>91</B>:9770&#173;9774. 
<P ALIGN="JUSTIFY">Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, 
A., Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C., and Sodroski, 
J. (1996). CD4-induced interaction of primary HIV-1 gp120 
glycoproteins with the chemokine receptor CCR-5. 
<I>Nature</I> <B>384</B>:179&#173;183. 
<P ALIGN="JUSTIFY">Wyand, M. S., Manson, K., Montefiori, D. C., Lifson, J. D., Johnson, R. P., 
and Desrosiers, R. C. (1999). Protection by live, attenuated simian 
immunodeficiency virus against heterologous challenge. 
<I>J. Virol.</I> <B>73</B>:8356&#173;8363. 
<P ALIGN="JUSTIFY">Wyatt, R., Desjardin, E., Olshevsky, U., Nixon, C., Binley, J., Olshevsky, V., 
and Sodroski, J. (1997). Analysis of the interaction of the human 
immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 
transmembrane glycoprotein. <I>J. Virol.</I> 
<B>71</B>:9722&#173;9731. 
<P ALIGN="JUSTIFY">Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., 
Hendrickson, W. A., and Sodroski, J. G. (1998). The antigenic structure of the HIV 
gp120 envelope glycoprotein. <I>Nature</I> 
<B>393</B>:705&#173;711. 
<P ALIGN="JUSTIFY">Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., and Sodroski, 
J. (1995). Involvement of the V1/V2 variable loop structure in the 
exposure of human immunodeficiency virus type 1 gp120 epitopes induced 
by receptor binding. <I>J. Virol.</I> <B>69</B>:5723&#173;5733. 
<P ALIGN="JUSTIFY">Wyatt, R. and Sodroski, J. (1998). The HIV-1 envelope glycoproteins: 
fusogens, antigens, and immunogens. <I>Science</I> 
<B>280</B>:1884&#173;1888. 
<P ALIGN="JUSTIFY">Zagury, J. F., Sill, A., Blattner, W., Lachgar, A., Le Buanec, H., Richardson, 
M., Rappaport, J., Hendel, H., Bizzini, B., Gringeri, A., Carcagno, M., 
Criscuolo, M., Burny, A., Gallo, R. C., and Zagury, D. (1998). Antibodies to the 
HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for 
the use of Tat toxoid as an HIV-1 vaccine. <I>J Hum 
Virol</I>:<B>282</B>&#173;92.
</BODY>
</HTML>
</td></tr>
	    <tr><td><table bgcolor="white" width="100%" align="center" cellpadding="0" cellspacing="0" border="0">
  <tr><td>&nbsp;</td></tr>
  <tr><td colspan=2 align=center>Questions or comments? Contact us at <a href="mailto:seq-info@t10.lanl.gov"><font color="#8f8fbd" face="helvetica">seq-info@t10.lanl.gov</font></a></td></tr>
  <tr><td>&nbsp;</td></tr>
</table>



</td></tr>
	  </table>  
        </td>
      </tr>	
    </table>
  </body>
</html>      

<!-- no autohandlers upstream -->


